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ABSTRACT 
 
The actinomycetes are a diverse group of Gram-positive, high G+C content bacteria of 
the order Actinomycetales. Many species of this group are of human interest as a result of 
their pathogenic nature and diverse metabolic properties. Those from the genus ocardia 
cause opportunistic infections of lung, brain and central nervous system, and cutaneous 
tissue. They are also producers of antibiotics and industrially important enzymes. As 
studies describing plasmids in this genus are limited, we have characterized a 4326 bp 
cryptic plasmid pYS1 from ocardia aobensis IFM 10795. Three open reading frames 
(ORFs) were predicted. Both sequence analyses and detection of single-stranded 
intermediates suggested a rolling-circle mechanism as the mode of replication of pYS1. 
Mutageneses and deletion analyses revealed both the predicted double- and single-
stranded origins to be indispensable in replication and thus lack of secondary signals for 
both leading and lagging strand synthesis. The replicon of pYS1 is broad-host-range and 
compatible to that of pAL5000 of mycobacteria, making it potentially useful in genetic 
manipulation of various actinomycetes. Insertion analyses showed orf1, despite its 
sequence similarity to plasmid transfer genes, is involved in plasmid stability rather than 
conjugation and is lethal in the absence of a functional orf3. This situation is somewhat 
analogous to the kil/kor system of pIJ101 of Streptomyces, except that orf3 was unrelated 
to korA and was shown by promoter-probe assays to encode a novel transcriptional 
repressor negatively regulating orf1 expression. 
Mycobacterium tuberculosis, the causative agent of tuberculosis, is responsible for 8 to 
10 million new cases of disease and 3 million deaths every year, many of which in 
HIV/AIDS patients. To identify novel drug targets in multi-drug resistant strains, DNA 
from Rhodococcus phages were tested and shown to be inhibitory to mycobacteria. To 
study the modes of action of products encodes by these genes, the lambda cI857 repressor 
and PR promoter system was tested for its ability to function as a tight genetic switch for 
toxic gene expression. Induction studies in both E. coli and mycobacteria indicate that 
strong mycobacterial promoters may be necessary to drive expression of toxic genes 
and/or the repressor gene. 
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1. I
TRODUCTIO
 
 
1.1 The actinomycetes 
The actinomycetes are a group of Gram-positive bacteria belonging to the order 
Actinomycetales. With 30 families (Fig. 1.1), this is one of the largest taxonomic groups 
within the eubacteria (Ventura et al., 2007).  
 
 
Figure 1.1. Tree showing the phylogenetics of Actinobacteria. Distances are based on 
1500 nucleotides of 16S rRNA. Bar = 5 nucleotides. Modified from Ventura et al. (2007). 
 
Actinomycetes are noted for the high G+C content of their DNA, ranging from 54% in 
some Corynebacterium (Cerdeno-Tarraga et al., 2003) to >70% in Streptomyces (Bentley 
et al., 2002; Ikeda et al., 2003) and Frankia (Normand et al., 2007). A variety of 
morphologies are displayed by actinomycete cells, including coccoid (e.g. Micrococcus), 
rod-coccoid (e.g. Arthrobacter), fragmenting hyphae (ocardia), to extensively branched 
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mycelia (e.g. Streptomyces) (Holt et al., 2000). In terms of lifestyle, these bacteria range 
from pathogens (e.g. Mycobacterium spp., ocardia spp., Rhodococcus spp., 
Corynebacterium spp., Propionibacterium spp.) to soil-dwellers (e.g. Streptomyces) to 
plant commensals (Leifsonia spp.) to nitrogen-fixing-symbionts (Frankia) (Holt et al., 
2000). This diversity is reflected in the genome sequences of these bacteria (Ventura et 
al., 2007), of which 96 have so far been deposited into the public database 
(http://www.ncbi.nlm.nih.gov/genome).  
The actinomycetes have been much studied by microbiologists and the biotechnology 
industry as a result of their diverse physiological and metabolic properties. They have 
been a rich source of secondary metabolites with pharmaceutical, chemical, agricultural, 
and industrial applications. For example, ~70% of antibiotics have been derived from 
products of actinomycetes, most notably the Streptomyces (Takahashi and Ōmura, 2003). 
The actinomycetes also secrete enzymes which degrade various xenobiotics, including 
polycyclic and halogenated aromatics, most of which are by-products of chemical 
manufacturing (Solyanikova et al., 2008). In this respect, the ocardioform 
actinomycetes, including the genera Gordonia, ocardia, Rhodococcus, Tsukamurella to 
mention a few, have shown promise in their biodegradative potential (Solyanikova et al., 
2008). As there is an ongoing need to discover natural products with novel activities, 
significant efforts are spent into screening environmental samples for rare actinomycetes 
as well as those commonly known for previously overlooked compounds (Gathogo et al., 
2004; Kurtbӧke, 2010; Takahashi and Ōmura, 2003). In support of these efforts, 
predictive modelling suggests that >150,000 bioactive metabolites are yet to be 
discovered from Streptomyces alone (Watve et al., 2001). 
Contrary to the economic and medical benefits brought about by the actinomycetes, a 
large fraction of morbidity and mortality caused by bacterial infections are due to the 
same group of organisms. Mycobacterium tuberculosis, the causative agent of 
tuberculosis (TB), is responsible for 8 to 10 million new cases of disease and 3 million 
deaths every year, many of which in HIV/AIDS patients (World Health Organization 
[WHO], 2006).  A major reason for its success as a pathogen is its ability to adapt to a 
wide range of conditions inside the human host, including the ability to stay dormant in a 
latent phase, the molecular mechanisms of which are not clearly understood (Ducati et al., 
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2006).  The genus Mycobacterium includes other pathogenic species of major 
significance, such as M. leprae, the causative agent of leprosy. 
The HIV/AIDS pandemic has also caused an increase in infections by other pathogenic 
actinomycetes, such as species from the genera ocardia, Rhodococcus, Gordonia, and 
Corynebacterium. They typically cause a granulomatous inflammatory reaction, which 
may progress to abscess formation (McNeil and Brown, 1994), although symptoms may 
vary at each of potential infection sites including lungs, brain, bones, pericardium, skin, 
among others (Salinas-Carmona, 2000). Combination antibiotic therapy is generally used 
to combat these infections, although multiple resistance to all major classes of drugs by 
some of these organisms has been reported (Cox et al., 2010; Glupczynski et al., 2006; 
Otsuka et al., 2006; Corti and Fioti, 2003; Hsueh et al., 1998; McNeil and Brown, 1994; 
Yazawa et al., 1993; Nordmann et al., 1992).   
 
1.2 The ocardia 
The genus ocardia currently contains 92 species characterized by molecular and 
phenotypic methods (Euzéby, 2010), although species have attracted widely different 
levels of attention. Although ocardia are ubiquitous in soil, >50 species have been 
identified as human or animal pathogens (Ambrosioni et al., 2010) causing nocardiosis, 
which is a rare opportunistic disease mainly affecting patients with deficiencies in cell-
mediated immunity such as acquired immunodeficiency syndrome (AIDS) patients or 
organ transplant patients. Incidence of disease in these groups of patients is 140-340 
times higher than in the immunocompetent population (Filice, 2005). The disease is 
manifested in three forms – pulmonary, cutaneous, and disseminated nocardiosis. 
Pulmonary nocardiosis is the most common form among immunosuppressed patients, 
while the cutaneous form is more frequent among immunocompetent patients 
(Ambrosioni et al., 2010). Disseminated nocardiosis frequently involves spreading of 
infection from the lungs to the central nervous system, brain, skin, and soft tissues 
(Ambrosioni et al., 2010). High rate of mortality is associated with the disease, reported 
to be between 7 and 44% for disseminated nocardiosis (McNeil and Brown, 1994). 
Treatment usually involves combination antibiotic therapy with sulfonamides and other 
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drugs and lasts for at least six months in the case of pulmonary nocardiosis (Corti and 
Villafañe-Fioti, 2003).  
The only genome sequence currently available for ocardia is that of . farcinica IFM 
10152 (Ishikawa et al., 2004). The genome was reported to be most similar to those of M. 
tuberculosis (Cole et al., 1998) and Corynebacterium glutamicum (Kalinowski et al., 
2003), and many genes with potential involvement in virulence were identified, although 
further work is needed to understand the mechanisms of virulence of this organism. The 
sequence also revealed at least 103 oxygenases, implying diverse metabolic capability of 
the organism (Ishikawa et al., 2004). 
 
1.3 Plasmids 
Plasmids are extrachromosomal elements capable of autonomous replication. Plasmids 
influence the biology of the host, sometimes dramatically; however, previous studies 
suggest no correlation between occurrence of plasmids in ocardia and their virulence 
(Provost et al., 1996; Qasem et al., 1999). Studies on plasmids may provide 
understandings of basic biological processes (Thomas, 2000). Plasmids also display great 
diversity in size, mode of replication and transfer, host range, and the set of genes they 
carry (Thomas, 2000), making them interesting elements for analysis. Information of 
such nature is limited in ocardia. Plasmids are major vehicles of horizontal gene flow, 
contributing to bacterial evolution. Among these, integrative and conjugative elements 
are increasingly recognized to allow rapid genetic adaptation to environmental alterations 
or occupation of entirely new niches (Burrus and Waldor, 2004). As tools, plasmids are 
indispensable in molecular biology, commonly used for cloning, expression, and 
mutagenesis. 
 
1.3.1 Occurrence of plasmids in ocardia 
A few previous studies have investigated the association between occurrence of plasmids 
in ocardia and their virulence or drug resistance. Provost et al. (1996) found plasmids 
in 27 out of 87 clinical isolates and could not associate virulence or drug resistance to 
them. These plasmids ranged in size from <8 kb to >50 kb, and multiple plasmids could 
be isolated from some strains (Provost et al., 1996). Although a bias was found in the 
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incidence of plasmid-bearing strains with respect to the species, area of isolation of the 
strains, and region of infection of the human body (Provost et al., 1996), the underlying 
reasons are not understood. Qasem et al. (1999) found plasmids in 8 out of 40 ocardia 
asteroides strains, ranging in size from <5 kb to >50 kb, and observed that their 
occurrence is not specific to particular species, source of origin, virulent strains, or drug 
resistance. This is in contrast to the closely related Rhodococcus equi, a pathogen of foals 
and immunocompromised humans, whose virulence is associated with the possession of 
vapA and vapB plasmids (von Bargen and Haas, 2009). 
 
1.3.2 Sequenced plasmids from ocardia 
So far full sequences of only five plasmids from ocardia have been deposited in the 
public database (www.ncbi.nlm.nih.gov). These include pNF1 and pNF2 (Ishikawa et al., 
2004), pXT107 (Xia et al., 2006), pC1 (Shen et al., 2006), and pYS1 (this work). For 
closely related actinomycetes such as Rhodococcus, Corynebacterium, and Streptomyces, 
full sequences of 22, 34, and 28 plasmids, respectively, are available in the database 
(www.ncbi.nlm.nih.gov), highlighting the comparative rarity of plasmid sequences from 
ocardia. 
 
1.3.2.1 p
F1 and p
F2 
Sequenced as parts of the genome of . farcinica IFM 10152 (Ishikawa et al., 2004), 
pNF1 and pNF2 are both circular plasmids of 184,027 bp and 87,093 bp, respectively. 
pNF1 was predicted to contain 160 protein-coding genes, 53 of which could be assigned 
potential functions, and was estimated to have a copy number of approximately one per 
chromosome. pNF2 was predicted to contain 90 protein-coding genes, 23 of which could 
be assigned potential functions, and was estimated to have a copy number of 
approximately two per chromosome. Sequences similar to parA and parB genes were 
identified on both plasmids, which are probably responsible for plasmid partitioning 
during cell division (Ishikawa et al., 2004).  
In a different study, using codon adaptation index (Sharp and Li, 1987) as an indicator of 
gene expressivity and ribosomal protein genes as a reference, highly expressed genes 
were predicted in the . farcinica genome (Wu et al., 2006). Genes on pNF1 and pNF2 
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were not as “expressive” as those on the chromosome, and only 1 out of predicted 571 
highly expressed genes was on the plasmid. No function has been assigned to this gene 
(Wu et al., 2006). 
 
1.3.2.2 pXT107 
Plasmid pXT107 is a circular cryptic plasmid of 4335 bp from ocardia sp. 107 (Xia et 
al., 2006). Of seven predicted open reading frames (ORFs), one had resemblance to those 
encoding rolling-circle-replication initiation proteins. Consistent with this mode of 
replication, the double- and single-stranded origins of replication (DSO and SSO) were 
predicted. The replicon of this plasmid was not functional in Streptomyces (Xia et al., 
2006).  
 
1.3.2.3 pC1 
Plasmid pC1 is a circular cryptic plasmid of 5841 bp from ocardia sp. C-14-1 (Shen et 
al., 2006). Of five predicted ORFs, one resembled those encoding a DNA recombinase 
and another to those encoding Ө-type replication proteins. The replicon of this plasmid 
was functional in ocardia and Rhodococcus but not in Streptomyces or Amycolatopsis. 
The replication gene of pC1 was not sufficient to allow stable inheritance of a 
recombinant plasmid, and its copy number was estimated to be approximately ten per 
chromosome (Shen et al., 2006). 
 
1.3.3 Other plasmids from ocardia 
There are several plasmids from ocardia that have been described but not sequenced. 
These include pHG33 (Sensfuss et al., 1986), pHG201 and pHG205 (Kalkus et al., 1990), 
and pNI100 (Liu et al., 2000). Plasmids pHG33 is a circular plasmid of approximately 
110 kb from ocardia opaca MR22 and carries genetic information for thallium 
resistance, which could be transferred to other strains of ocardia by conjugation at a 
frequency of 1e-1 to 1e-2 per donor (Sensfuss et al., 1986). Plasmid pHG201 and 
pHG205 are linear megaplasmids of 270 kb and 280 kb, respectively, from two different 
strains of . opaca. Both plasmids carry genetic information for soluble hydrogenase and 
ribulose-biphosphate which could be transferred to other stains by conjugation (Kalkus et 
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al., 1990).  Plasmid pNI100 is a cryptic circular plasmid of 19 kb from ocardia italica 
CCRC 12359 which contains a gene predicted to encode a protein that initiates rolling-
circle-replication. This conjugative plasmid has a replicon which is functional in 
Streptomyces (Liu et al., 2000).  
 
1.4 Aim of part one – Plasmid from ocardia 
More plasmids from ocardia should be described to reveal their sizes, modes of 
replication and transfer, host ranges, and functions of genes they carry. The aim of this 
work is to characterize a plasmid from ocardia and highlight these features. 
 
1.5 Bacterial resistance to antibiotics 
Soon after any antibacterial agent is introduced for clinical use, resistance arises.  There 
are four general resistance mechanisms: drug inactivation, target alteration, prevention of 
drug influx, and drug efflux (Putman et al., 2000). Scientists have responded to resistance 
by modifying already existing drugs or with new classes of drugs. For example, 
penicillinase-stable penicillins, and second generation aminoglycosides were produced to 
counteract resistant organisms. However, resistance has emerged to these newer agents in 
all cases, thereby repeating the cycle (Bush, 2004). Usage of a combination of existing 
drugs is not a complete solution, as evidenced by the emergence of multidrug-resistant 
pathogens (Livermore, 2004). In order to keep ahead of resistance, development of new 
antimicrobial agents is vital. 
 
1.5.1 Emergence of multi-drug-resistant strains of M. tuberculosis 
A recent joint report by the US Centers for Disease Control and Prevention (CDC) and 
the WHO (CDC, 2006) has highlighted the emergence of extensively drug resistant 
(XDR) TB, caused by organisms resistant to at least isoniazid and rifampicin among the 
first-line drugs (i.e. multiple drug resistant [MDR] TB) and to at least three of six main 
classes of second-line drugs. XDR-TB has been reported in at least 17 countries in all 
continents (CDC, 2006). In a hospital in Kwazulu-Natal Province of South Africa, there 
has been a deadly outbreak of XDR-TB which killed 52 out of 53 patients, with a median 
survival period of only 16 days since the first sputum specimen collection (Ghandi et al., 
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2006). It is clear that there is an urgent necessity to identify additional molecular targets 
and develop novel antimicrobial agents. 
 
1.6 Antibacterial drug discovery 
Despite the emergence of multidrug-resistant bacteria, there has been a serious fall-off in 
development of novel antibacterials in the past several decades. The oxazolidinone 
linezolid and cyclic lipopeptide daptomycin have been the only structurally novel 
antibiotics to be introduced in over thirty years (Hamad, 2010). Most antibiotics 
introduced since 1968 have been modifications of already existing ones (Powers, 2004). 
One reason for this decline is difficulty in target identification (Projan and Shlaes, 2004). 
Traditionally, antibiotics were developed by screening natural sources for molecules with 
antimicrobial effects. Most recently, searches for antibacterials have utilized 
bioinformatics to identify essential and conserved ORFs in bacterial genomes which may 
be potential targets (Thomson et al., 2004). Currently, complete genome sequences of 
1312 bacterial strains are publicly available (http://www.ncbi.nlm.nih.gov/genome), 
including those of many clinically important pathogens. However, after more than 15 
years since the beginning of the genomics era, not a single antimicrobial agent has been 
developed by this approach (Thomson et al., 2004). Other novel methods currently 
employed for the discovery of new targets are transcriptional profiling and proteomic 
analysis (Bandow et al., 2003). Besides searching the bacterial genomes, various 
potential antimicrobial agents are currently under investigation. These include 
antimicrobial peptides, bacteriophages, and probiotic bacteria (Gillor et al., 2005). 
 
1.6.1 Eukaryotic antimicrobial peptides 
Gene-encoded, ribosomally synthesized antimicrobial peptides (AMPs) are widely 
distributed in nature and produced by both eukaryotes and prokaryotes. AMPs are 
produced in phagocytes and mucosal epithelial cells of mammals, haemolymph of insects, 
and skin of amphibians, where they provide an early defence against invading 
microorganisms (Boman, 1995). Some of well-characterized animal AMPs are defensins 
of humans, cecropins of insects, and magainins of frogs. Animal AMPs display a broad 
spectrum of activity against both Gram-positive and -negative bacteria. Although various 
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AMP structures exit, those for which the mode of action has been elucidated act by 
membrane permeabilization (Papagianni, 2003).  Examples of eukaryotic AMPs are 
shown in Table 1.1. 
 
Table 1.1. Examples of eukaryotic AMPs grouped according to structure 
Structure Peptide Source 
Abaecin Insects 
Bac-5 Sheep  High content of certain amino acid 
Prophenin Pigs 
α-Defensins Humans 
Insect defensins Insects Intramolecular disulfide bridges 
Plant defensins Plants 
Magainins Frogs 
Bombinins Frogs Amphiphilic α-helical structure 
Cecropin Insects 
(Modified from Papagianni, 2003) 
 
1.6.2 Prokaryotic antimicrobial peptides 
Prokaryotic AMPs, known as bacteriocins, are a large and diverse group of toxins found 
in both bacteria and archaea. They are narrow spectrum antimicrobials and use a variety 
of killing mechanisms. Lactic acid bacteria produce the best-known Gram-positive 
bacteriocins, the lantibiotics, which include nisin, a commercially used food preservative 
(Asaduzzaman and Sonomoto, 2009). Bacteriocins produced by Gram-positive bacteria 
act by membrane depolarization, membrane leakage, and cell wall synthesis inhibition 
(Pag and Sahl, 2002). Well known bacteriocins from Gram-negative bacteria include 
colicins, microcins, both of which are produced by E. coli, and pyocins produced by 
Pseudomonas spp. Modes of action by colicins include depolarization of cell membrane, 
degradation of DNA and RNA, and inhibition of cell wall and protein synthesis (Braun et 
al., 1994). Microcins target cell membranes and biosynthesis of DNA, RNA, and proteins 
(Destoumieux-Garzón et al., 2002; Pons et al., 2002). Pyocins act by forming pores on 
cell membranes and degrading DNA and RNA (Duport et al., 1995; Gillor et al., 2005; 
Parret and De Mot, 2000). Different groups of bacteriocins and their targets are 
summarized in Table 1.2. 
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Table 1.2. Bacteriocin types and their targets 
Bacteriocin Class/type Target 
IA, II cell membrane 
IB cell wall synthesis: lipid II 
Lactic acid 
bacteria 
bacteriocins III Unknown 
A, B, E1, Ia, Ib, K, 
N 
cell membrane 
E2, E7, E8, E9 DNA 
E3, E4, E6 protein synthesis: 16S rRNA 
E5, D protein synthesis: tRNA  
Colicins 
M cell wall synthesis: lipid carrier 
DNA replication: β subunit, DNA gyrase 
(gyrB) 
Transcription: β' subunit, RNA polymerase 
Modified 
Protein synthesis 
Microcins 
Non-modified cell membrane 
R, F cell membrane 
DNA 
cell membrane 
Pyocins 
S 
protein synthesis: tRNA 
 
 
1.6.3 Bacteriophage-mediated antimicrobials 
Bacteriophages hold potential for the development of novel antimicrobials. This may 
be possibly done in three different ways: 1) phage therapy, 2) phage lytic enzymes, 
and 3) target identification. 
 23 
1.6.3.1 Phage therapy 
The idea of using bacteriophages, the most abundant organisms on the planet, as 
antimicrobials is not new. After d’Hérelle coined the term “bacteriophage” in 1916, 
he successfully treated a patient with severe dysentery using a phage preparation 
taken orally and set up phage therapy trials across the globe (Stone, 2002). Phage 
therapy was extensively tested, succeeding against diseases such as dysentery, 
typhoid, paratyphoid, cholera, pyogenic and urinary-tract infections (Thacker, 2003). 
However, overall results were variable; due to ineffective trials and the advent of 
antibiotics, the use of bacteriophages as antimicrobials was abandoned. In hindsight, 
the ineffective trials were caused by prescription of wrong phages or those which 
were no longer viable (Pirisi, 2000). 
Although abandoned in the west, phages continued to be used as antibacterial agents 
in the former Soviet Union and Eastern Europe. For example, during a civil war in 
the early 1990s, Georgian soldiers carried spray cans with a phage suspension 
effective against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, 
Streptococcus pyogenes, and Proteus vulgaris (Stone, 2002). In some Russian 
villages, civilians relied exclusively on phages as the cheaper option compared to 
antibiotics (Pirisi, 2000).  Although some data have been published, most do not exist 
in English. 
Due to the emergence of multidrug-resistant pathogenic bacteria, there has been a 
recent revival in interest in phage therapy. One advance in phage therapy is against 
vancomycin-resistant enterococci, for which clinical trials are currently underway 
(Bradbury, 2004). 
 
1.6.3.2 Phage lytic enzymes 
Instead of phage therapy, there has been a recent interest in purification and 
characterization of phage lytic enzymes, which can be used to combat target bacteria. 
Phage enzymes directed against Gram-positive pathogens, including Streptococcus 
pneumoniae and Bacillus anthracis, have been isolated and shown to successfully 
destroy these pathogens both in vitro and in vivo (Loeffler et al., 2001; Schuch et al., 
 24 
2002). For example, lytic enzyme Pal from S. pneumoniae phage Dp-1 has been 
shown to kill fifteen common serotypes of the bacterium, including highly penicillin-
resistant strains (Loeffler et al., 2001). Lysin PlyG from B. anthracis phage γ is host 
specific, binding to cell wall antigens not recognized by current antibiotics (Schuch et 
al., 2002). 
 
1.6.3.3 Phage-mediated target identification 
Another approach to phage-mediated antimicrobial development is target 
identification. This has been exemplified by a study by Liu et al. (2004), who 
screened the genomes of S. aureus phages for ORFs which were inhibitory to the host 
bacterium. Targets of these antibacterial ORFs were then biochemically identified, 
followed by a high-throughput screen to discover small molecules which could 
inhibit the host cell by the same mechanism as the phage proteins. Using this 
approach, 31 novel polypeptide families were identified from 26 S. aureus phages, 
several of which were inhibitory to DNA replication and transcription (Liu et al., 
2004). This approach may be a powerful method to identify effective targets in the 
host, as phages are believed to have evolved multiple strategies to disable host cells. 
Although there is potential in the traditional phage therapy or in the use of their lytic 
enzymes, the development of novel antibiotics by recruiting phages in the 
identification of new targets may be the best phage-mediated antimicrobial. Small 
antimicrobial molecules that are commonly used have been selected to have a 
sufficient degree of distribution in human tissues and appropriate levels of other 
pharmacokinetic properties. Therefore, novel antibiotics are expected to better meet 
these criteria of an effective medicine compared to a phage particle or even a lytic 
protein, whose complexity is much higher and size much larger (Projan, 2004).  
 
1.7 Phage diversity 
A major factor contributing to the potential of phage-mediated target identification is 
the abundance of these viruses in nature. For instance, >50 different phages capable 
of infecting E. coli have been included in the Universal Virus Database 
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(http://ncbi.nlm.nih.gov/ICTVdb/Ictv/index.htm). In addition, it has been calculated 
that there are ~10 million bacterial species (Curtis et al., 2002). If each of these is a 
host for ≥ 10 different phages, then the number of phage species may be at least 100 
million. 
Despite the predicted abundance of phages, the use of phage ORFs in identifying 
novel targets will be effective only if phages employ diverse mechanisms in 
inhibiting their hosts. If all phages possess similar genes and use identical 
mechanisms to act against their hosts, there are limited prospects of discovering new 
bactericidal mechanisms. 
Recent comparative genomic analyses of phages infecting Mycobacterium smegmatis 
(Hatfull et al., 2010; Hatfull et al., 2006; Pedulla et al., 2003), P. aeruginosa (Kwan 
et al., 2006), and S. aureus (Kwan et al., 2005) imply enormous diversity in their 
genetic makeup. Less than 10% of predicted protein families from 60 sequenced 
mycobacteriophage genomes could be assigned functions based on a database search 
(Hatfull et al., 2010). From 18 P. aeruginosa phage genomes and 27 S. aureus phage 
genomes, 35% and 45%, respectively, of predicted ORFs had sequence similarity to 
those previously reported (Kwan et al., 2006; Kwan et al., 2005). Moreover, many of 
these phage genomes display little relationship to each other (Hatfull et al., 2010; 
Kwan et al., 2005; Kwan et al., 2006), suggesting that each individual phage 
possesses unique genes. Further support for these findings comes from a shotgun 
sequencing of uncultured viral communities in sea water, which have shown that 
~75% of phage sequences are novel (Breitbart et al., 2002). 
Average number of ORFs from the sequenced M. smegmatis phages, P. aeruginosa 
phages, and S. aureus phages, are 114, 105, and 80, respectively (Hatfull et al., 2010; 
Kwan et al., 2006; Kwan et al., 2005). If a conservative assumption is made that all 
100 million phage species in the world possess 50 ORFs, of which 50% are unknown, 
then there are 2.5 billion phage ORFs to be discovered (Rohwer, 2003). It is likely 
that only a small fraction of these ORFs participate in killing the host; however, 
phages present a potentially enormous pool of genes from which a large number of 
novel bactericidal mechanisms may be identified. 
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1.8 Phage lethal genes 
Expression of phage genes may be early, middle, or late, depending on the time at 
which their transcription begins after initiation of infection. Many lethal genes are 
expressed early, as they take part in shutoff of host macromolecular biosynthesis 
(Miller et al., 2003). Knowledge of mechanism by which a phage functions in a host 
is limited. Similarly, an overwhelming majority of genes believed to be lethal are 
uncharacterized. Studies (Miller et al., 2003) also suggest that a single phage may 
possess several such genes. A small number of them have been studied; when tested 
individually, a majority of these bactericidal genes have been proven to be 
dispensable during infection (Abedon et al., 2001; Kutter et al., 1994a; Kutter et al., 
1994b), indicating that a single phage has multiple strategies for killing a host. 
Therefore, with respect to novel antimicrobial target identification, not only does the 
potential of phages attribute to the number of species and their genetic heterogeneity, 
but also to the variety of targets attacked by individual phage species. It should also 
be noted that killing of hosts may not be the only function of many lethal genes; they 
may have other benefits for phage replication, while being deleterious to the host. 
Some of the studied lethal phage genes are summarized below. 
 
1.8.1 Phage T4 
Studies on E. coli phage T4 began in the 1940s, but of its ~300 ORFs, 127 still have 
no assigned function (Miller et al., 2003). Many of these unknown genes are 
unclonable, reinforcing the notion that they are lethal to the E. coli host, and a high 
level of their expression occurs early in the infection cycle (Miller et al., 2003).   
One example of a T4 lethal gene is alc, which uniquely recognizes the rapidly 
elongating form of RNA polymerase complex, leading to termination of transcription 
(Kutter et al., 1994). Another example is the Alt protein, which is packaged in the 
capsid and transported with the phage DNA into the cell upon infection. Alt functions 
by ADP-ribosylating the α subunit of the host RNA polymerase (Igarashi et al., 1991). 
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T4 possesses at least two other ADP-ribosyltransferase genes, modA and modB, 
which are known to be lethal to the host.  ModA ADP-ribosylates both α subunits of 
the host RNA polymerase (Tiemann et al., 1999), whereas ModB acts on the 
translation machinery of the ribosome by ADP-ribosylating the S1 protein, elongation 
factor EF-Tu, and the chaperone “trigger factor” (Tiemann et al., 1999).  
Other T4 gene products inhibiting translation are Lit and Gol proteins. Lit cleaves the 
host EF-Tu at a region which is central to the Mg-GTP-binding domain (Yu and 
Snyder, 1994). This process is aided by Gol, which stabilizes the EF-Tu-GDP open 
complex, making it accessible for cleavage (Bingham et al., 2000). Gol is also a part 
of a T4 head capsid protein, suggesting its dual function (Bingham et al., 2000). 
Intron- or intein-encoded DNases with highly specific recognition sequences are 
called homing endonucleases, which help to disseminate the intron/intein into 
specific regions of the genome. T4 possesses >15 such genes (Chevalier and Stoddard, 
2001). Although purpose served by the introns/inteins is not clear, these 
endonucleases have been shown to be bactericidal (Sharma et al., 1992). 
 
1.8.2 Phage T7 
T7 is an E. coli phage which has a number of genes implicated in host transcription 
shutoff. Gp2 binds to promoters of host DNA, thereby abolishing promoter 
recognition by the host RNA polymerase (Nechaev and Severinov, 1999). Gp0.7 is a 
serine/threonine protein kinase, which phosphorylates various biosynthetic 
components: among the transcription machinery includes the β' subunit of RNA 
polymerase (Zilling et al., 1975); RNase III, which is responsible for mRNA 
processing (Mayer and Schweiger, 1983); RNase E, which is involved in mRNA 
decay (Marchand et al., 2001); among the translation machinery includes IF1, IF2, 
IF3, elongation factor G, and ribosomal proteins S1 and S6 (Robertson et al., 1994). 
Phosphorylation of the β' subunit of RNA polymerase is lethal (Severinova and 
Severinov, 2006). Whether host viability is affected by the phosphorylation of other 
targets is yet to be discovered. 
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1.8.3 Phage lambda (λ) 
Lambda is an extensively studied E. coli phage, although most works have focused 
on non-lethal genes. One of few identified bactericidal gene products is peptidyl-
tRNA hydrolase, which cleaves peptidyl-tRNA and aminoacyl-tRNA (Garcia-
Villegas et al., 1991). In addition, lambda p gene causes host death by inhibiting the 
binding of template DNA and ATP to the DnaA protein (initiator protein), thereby 
preventing DNA replication to begin (Datta et al., 2005). CII gene product is another 
inhibitor of host DNA replication. Although the exact mechanism is unknown, it 
seems to interfere with the association of DNA helicase with origin of replication 
(Kędzierska et al., 2003). Another lethal gene product, Kil protein, inhibits cell 
division by interacting with components of the cell envelope (Sergueev et al., 2001). 
 
1.8.4 Phage SPO1 
Phage SPO1 of Bacillus subtilis possesses a cluster of early genes in a region named 
“host-takeover module”, including ~24 of mostly unknown function but believed to 
be involved in inhibition of host biosynthesis (Stewart et al., 1998). An example of 
such gene is e3, whose expression leads to inhibition of DNA, RNA, and protein 
synthesis in both B. subtilis and E. coli (Wei and Stewart, 1993). Products of genes 
44, 50, and 51 cause inhibition of host transcription, possibly by binding to RNA 
polymerase (Sampath and Stewart, 2004). 
 
1.8.5 Phages with ssD
A or ssR
A genomes 
Where phages with dsDNA genomes encode two to five proteins to carry out host 
lysis, phages with small, single-stranded nucleic acids usually have only a single gene 
required for rupturing host cells (Bernhardt et al., 2001). Instead of attacking pre-
existing peptidoglycan, these phages interfere with cell wall synthesis, thereby 
causing weakness in the wall, which collapses from osmotic pressure from within. 
For example, ssDNA phage ϕX174 encodes a single lytic enzyme, E, which blocks 
MraY, a bacterial membrane protein responsible for transfer of murein precursors to 
lipid carriers that transport it through the cell membrane (Bernhardt et al., 2000). In 
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the ssRNA genome of phage Qβ is the a2 gene, encoding a protein inhibiting MurA, 
another essential enzyme for cell wall synthesis (Bernhardt et al., 2001). Protein A2 
has multiple functions including adsorption to the host sex pilus and protection 
against ribonucleases (Bernhardt et al., 2001). 
 
1.8.6 Inhibitory genes from Rhodococcus phages  
In a previous study (Shibayama, 2006), four novel Rhodococcus phages (FND1, 
WTS1, KZA1, and PGS1) were isolated from soil and characterized. Libraries of 
their nucleic acid were constructed and screened for clones inhibitory to Rhodococcus 
erythropolis. Nine clones were characterized, and minimum necessary DNA for 
inhibitory activity sequenced. Of 18 ORFs predicted on these DNA, 13 could not be 
assigned a function. Genes similar to ones in databases apparently interfered with 
DNA metabolism, protein synthesis, or integrity of plasma membrane. Sequence 
analyses of inhibitory clones are summarized in Table 1.3. 
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1.9 Currently available inducible expression systems in Mycobacterium 
To study the action of the above inhibitory genes, a system that allows their 
expression to be tightly switched off is necessary. Inducible expression systems have 
been described for both Rhodococcus and Mycobacterium. In Rhodococcus pTip 
vectors (Nakashima and Tamura, 2004), with which expression is induced by 
thiostrepton, have been described. In Mycobacterium pMind vector (Blokpoel et al., 
2005), pTACT and pHLEGM vectors (Carroll et al., 2005), pUV and pME vectors 
(Ehrt et al., 2005), and pMHA vectors (Hernandez-Abanto et al., 2006), all with 
which expression is induced by tetracycline, have been described. Expression levels 
using some of these vectors can be controlled by the dosage of the inducer. However, 
leaky expression has been detected with each of the above vectors, which may be 
problematic for genes encoding potent inhibitors.  
 
1.10 Lambda cI repressor  
The E. coli phage lambda is capable of both lytic and temperate lifestyles. The latter 
is characterized by the integration of the phage genome into the host chromosome. 
Maintenance of this otherwise lethal state is achieved by the phage-encoded cI 
repressor, whose function is to prevent transcription of cro and other genes necessary 
to enter the lytic lifestyle. Their transcription is negatively regulated by the binding of 
the lambda repressor to the operators OR1 and OR2 which overlap the promoter PR 
that is responsible for driving transcription of the cro gene (Ptashne, 2004). As leaky 
expression of cro should be lethal to the host, the cI repressor is a good candidate for 
a component of a tight genetic switch. A temperature sensitive mutant of the repressor, 
cI857 (Sussman and Jacob, 1962), has been widely used to allow successful inducible 
expression in E. coli and other Gram-negatives, and with limited success in Gram-
positives (Valdez-Cruz et al., 2010). This repressor is functional at ~33°C but loses its 
ability to bind the operators at ~42°C, thereby allowing a temperature-sensitive 
transcriptional control of genes downstream of PR. This repressor may potentially be 
used to construct a tight genetic switch in Mycobacterium.    
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1.11 Aim of part two – Testing of phage genes for inhibition against 
Mycobacterium and construction of a tight genetic switch to control their 
expression 
Multidrug-resistance in M. tuberculosis urges for identification of new susceptibility 
targets. As the preliminary genetic analysis of above phages has suggested the 
presence of novel bactericidal mechanisms, these inhibitory genes should be tested for 
activity in Mycobacterium. To understand the modes of action of the encoded proteins, 
an inducible expression system functional in this genus is necessary. The aim is 
therefore to construct a system where expression of a cloned inhibitory gene can be 
controlled by the cI857-PR system constituting a tight genetic switch. 
 
1.12 Phage anti-restriction 
Bacteria have evolved protective mechanisms against attacking phages at almost all 
stages of phage life cycle (Krüger and Bickle, 1983). One of these is the restriction 
and modification system, which attacks foreign DNA inside the cells while protecting 
their own. This function is important enough to have apparently evolved 
independently several times, as exhibited by the presence of different classes of 
restriction modification systems. In order to survive restriction, phages have evolved 
anti-restriction mechanisms including 1) blocking of restriction enzyme, 2) phage-
encoded modification of DNA, 3) stimulation of host modification functions, 4) 
possession of unusual bases, 5) co-injection of protective proteins, 6) destruction of 
endonuclease co-factors, and 7) loss of restriction sites (Krüger and Bickle, 1983). Of 
these mechanisms, ones that are functional in vitro upon purification of DNA are the 
modification of DNA, presence of unusual bases, and absence of restriction sites. 
These have been mostly studied in E. coli phages and B. subtilis phages.   
Modified bases refer to those whose modifications take place after the synthesis of 
normal DNA. B. subtilis phages SPβ and ϕ3T possess a methyltransferase gene that 
methylates the central cytosine in the sequence GGCC, which is the recognition 
sequence of endonuclease BsuRI of B. subtilis (Cregg et al., 1980). E. coli phage Mu 
produces the Mom protein, which acetimidates ~15% of its adenine residues, thereby 
producing N6-(1-acetamido)adenine, making its DNA resistant to type I and III 
enzymes and partially resistant to type II enzymes (Hattman, 1980). E. coli phages T2 
and T4 encode a methyltransferase that methylates a fraction of adenine residues to 
produce 6-methylaminopurine (Gold et al., 1966). Shigella sonnei phage DDVI 
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methylates the 7 position of guanine in about a quarter of its DNA, producing 7-
methylguanine (Nikolskaya et al., 1979). 
Unusual bases are those which are not adenine, cytosine, guanine, or thymine, and are 
produced at the level of nucleotide metabolism. Various unusual bases in phages have 
been discovered, summarized in Table 1.4. Their structures are illustrated in Figure 
1.2. 
 
Table 1.4. Unusual bases in phage DNA 
Phage Host Base change 
% of 
normal 
base 
replaced 
Reference 
T4 E. coli 
5-hydroxymethylcytosine 
(glucosylated) replacing 
cytosine  
100% 
Lehman and 
Pratt, 1960; 
Wyatt and 
Cohen, 1953 
SPO1 B. subtilis 
5-hydroxymethyluracil 
replacing thymine 
100% 
Kallen et al., 
1962 
PBS1 B. subtilis Uracil replacing thymine 100% 
Takahashi 
and Marmur, 
1963 
SP15 B. subtilis 
5-dihydroxypentyluracil 
replacing thymine 
41% 
Brandon et 
al., 1972 
SP10 B. subtilis 
α-glutamylthymine replacing 
thymine 
15 – 
20% 
Krajewska 
and Shugar, 
1971 
χP12 
Xanthomonas 
oryzae 
5-methylcytosine replacing 
cytosine 
100% 
Ehrlich et al., 
1975 
S2L 
Synechococcus 
elongates 
2-aminoadenine replacing 
adenine 
100% 
Kirnos et al., 
1977 
ϕW14 
Pseudomonas 
acidovorans 
α-putrescinylthymine 
replacing thymine 
50% 
Bott and 
Strauss, 1965 
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Figure 1.2. Structures of unusual bases in phage DNA (Modified from Warren, 1980). 
 
Loss of endonuclease restriction sites has been shown in many phages, by comparing 
the actual number of recognition sites to their statistically expected number. For 
example, the recognition sequence of B. subtilis endonuclease BsuRI, GGCC, does 
not occur once in B. subtilis phage ϕ1, although 400 such sites can be predicted 
statistically in its genome (Kawamura et al., 1981). Phage SPO1, which possesses the 
unusual base hydroxymethyluracil, also lacks the same recognition sequence (Reeve 
et al., 1980), showing multiple strategies used to counter restriction. 
In a previous study (Shibayama, 2006) anti-restriction mechanisms were detected in 
two Rhodococcus phages. Results from DNA digestion and cloning have suggested 
the presence of modified or unusual bases in phages WTS1 and KZA1. 
 
1.13 Aim of part three – Unusual or modified bases in Rhodococcus phage 
nucleic acids 
The aim of this study is to gain further evidence supporting the presence of unusual or 
modified bases in phage WTS1 and KZA1 nucleic acids. Where evidence affirms 
their presence, the aim is to elucidate their structures. 
 
1.14 Aims of this study 
To recapitulate, the aim of each part of this study is: 
5-hydroxymethylcytosine 5-methylcytosine Uracil 
5-hydroxymethyluracil α-putrescinylthymine 5-dihydroxypentyluracil 
α-glutamylthymine 2-aminoadenine 
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Part one – Plasmid from ocardia 
To characterize a plasmid from ocardia to highlight features such as mode of 
replication and transfer, host range, and functions of genes it carries. 
 
Part two – Testing of phage genes for inhibition against Mycobacterium and 
construction of a tight genetic switch to control their expression 
To test the previously isolated Rhodococcus phage genes for inhibitory activity 
towards Mycobacterium and to construct an inducible expression system using the 
lambda cI857-PR that will allow the control of expression of these inhibitory genes in 
this organism. 
 
Part three – Unusual or modified bases in Rhodococcus phage nucleic acids 
To gain further evidence supporting the presence of unusual or modified bases in the 
nucleic acids of phages WTS1 and KZA1 and to elucidate their structures.  
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2. MATERIALS A
D METHODS 
 
For all solutions and reagents see the Appendix. 
 
2.1 Bacteria and bacteriophages  
Bacteria, excluding those for plasmid screening and plasmid host range study, are 
listed in Table 2.1. Strains for plasmid screening are listed in Table 2.2. Those for 
plasmid host range study are listed in Table 2.3. Phages are listed in Table 2.4. 
 
Table 2.1. Bacterial strains used in this study 
Species and strain Relevant characteristics Source/reference a 
Escherichia coli   
     MM294-4 hsdR17 endA1 gyrA Quan et al., 1997 
     MM294-4 [λ] MM294-4 lysogenized with λ (cI857 S7) Quan et al., 1997 
     GM2929 dcm-6 dam13::Tn9 recF143, hsdR2 CGSC 
ocardia aobensis   
     IFM 10795 Source of pYS1 IFM 
ocardia nova   
     IFM 10797 Host for plasmid construction in ocardia IFM 
ocardia mexicana   
     IFO 3927 Control strain from which total DNA was 
used for TLC 
IFO 
Rhodococcus erythropolis   
     SQ1 Highly transformable derivative of ATCC 
4277 
Quan and Dabbs, 1993 
Mycobacterium smegmatis   
     mc2155 Highly transformable derivative of mc26 Snapper et al., 1990 
     mc2155r Spontaneous rifampicin-resistant mutant of 
mc2155 
This work 
Bacillus subtilis   
     1A3 Host for phages PBS1 and SPO1 BGSC 
Staphylococcus aureus   
     unknown strain Host for phage KG3 Green, 2007 
a CGSC, Coli Genetic Stock Center; IFM, Institute for Food Microbiology, currently 
Medical Mycology Research Center; IFO, Institute of Fermentation, Osaka; BGSC, 
Bacillus Genetic Stock Center. 
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Table 2.2. Bacterial strains screened for plasmids 
Species IFM strain 
ocardia farcinica 10757 
 10759 
 10764 
 10773 
 10779 
 10792 
  
ocardia cyriacigeorgica 10752 
 10762 
 10778 
 10793 
 10796 
 10802 
  
ocardia abscessus 10763 
 10765 
 10777 
 10788 
 10794 
  
ocardia brasiliensis 10745 
 10748 
 10781 
 10798 
  
ocardia asteroides 10756 
 10791 
  
ocardia nova 10768 
 10797 
  
ocardia aobensis 10785 
 10795 
  
ocardia transvalensis 10753 
 10761 
  
ocardia otitidiscaviarum 10786 
  
ocardia beijingensis 10772 
All strains were obtained from the Medical Mycology Research Center. 
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Table 2.3. Bacterial strains used for plasmid host range study 
Species and strain Source / reference a 
ocardia aobensis IFM 10795 IFM 
ocardia aobensis IFM 10795c this work 
ocardia nova IFM 10797 IFM 
ocardia brasiliensis IFM 10745 IFM 
ocardia farcinica IFM 10757 IFM 
Mycobacterium smegmatis mc2155 Snapper et al., 1990 
Mycobacterium parafortuitum IFM 0490 IFM 
Gordonia rubropertincta ATCC 25593 ATCC 
Rhodococcus erythropolis ATCC 4277 ATCC 
Rhodococcus rhodochrous 01 E. Dabbs 
Rhodococcus equi ATCC 14887 ATCC 
Arthrobacter oxydans C7 E. Dabbs 
Streptomyces lividans TK23 Hütter et al., 1985 
Escherichia coli MM294-4 Quan et al., 1997 
a ATCC, American Type Culture Collection. 
 
Table. 2.4. Bacteriophage stains used in this study 
Phage Host species Source reference 
FND1 R. erythropolis Shibayama, 2004 
WTS1 R. erythropolis Shibayama, 2007 
KZA1 R. erythropolis Shibayama, 2007 
PGS1 R. erythropolis Shibayama, 2007 
KG3 S. aureus Green, 2007 
λ E. coli CGSC 
T4 E. coli CGSC 
PBS1 B. subtilis BGSC 
SPO1 B. subtilis BGSC 
 
 
2.1.1 Media and growth conditions 
All cultures, except those of ocardia and Gordonia, were grown in Luria-Bertani 
(LB) broth with good aeration. All cultures were grown at 37 °C except those of E. 
coli MM294-4[λ], Rhodococcus, M. parafortuitum, A. oxydans, and S. lividans, which 
were grown at 30 °C. 
 
Cultures of ocardia and Gordonia were grown in Brain Heart Infusion (BHI) broth 
supplemented with 1% glucose and 1% glycerol with good aeration. All ocardia 
were grown at 37 °C and Gordonia at 30 °C. 
 
For all plate cultures, growth media were solidified with 1.5% agar. 
 39 
 
For short-term storage, all strains were kept on agar plates at 4°C. For long-term 
storage, cells suspended in 30% glycerol were stored at -70°C. 
 
Rhodococcus phages and Staphylococcus phages were propagated according to 
previously reported multiplicities of infection (MOI) (Green, 2007; Shibayama 2004; 
Shibayama, 2007). Optimal MOI for the propagation of Escherichia phages and 
Bacillus phages were empirically determined.   
 
2.2 Plasmids 
All plasmids used in this study are listed in Table 2.5. 
 
Table 2.5. Plasmids 
Plasmid Description Reference/source 
pYS1 4326 bp cryptic plasmid from . aobensis IFM 10795 This study 
pK18 E. coli vector with kanamycin resistance marker Pridmore, 1987 
pYS1R1 Position 1904-3966 of pYS1 amplified with primers PYS1Rep48F1 and 
PYS1Rep9R1 and ligated into heI site of pK18 
This study 
pYS1R1S1 Sequence TAGCCA of second exposed loop of predicted SSO mutagenized in-
vitro to TGCAGA in pYS1R1 
This study 
pYS1R1D1 Sequence TTGGAA of predicted DSO mutagenized in-vitro to AGATCT in 
pYS1R1 
This study 
pYS1R2 Position 1904-3597 of pYS1 amplified with primers PYS1Rep48F1 and 
PYS1Rep14R1 and ligated into heI site of pK18 
This study 
pYS1R3 Position 1990-3597 of pYS1 amplified with primers PYS1Rep1990F1 and 
PYS1Rep14R1 and ligated into heI site of pK18 
This study 
pYS1R4 Position 2050-3597 of pYS1 amplified with primers PYS1Rep2050F1 and 
PYS1Rep14R1 and ligated into heI site of pK18 
This study 
pYS1R5 Position 2100-3597 of pYS1 amplified with primers PYS1Rep2100F1 and 
PYS1Rep14R1 and ligated into heI site of pK18 
This study 
pYS1R6 Position 2182-3966 of pYS1 amplified with primers PYS1Rep54F1 and 
PYS1Rep9R1 and ligated into heI site of pK18 
This study 
pYS1R7 Position 2182-3597 of pYS1 amplified with primers PYS1Rep54F1 and 
PYS1Rep14R1 and ligated into heI site of pK18 
This study 
pNV18/19 ocardia – E. coli shuttle vector Chiba et al., 2007 
pUC4K E. coli plasmid containing excisable aph gene from Tn903 Amersham 
pYS1K1 304 bp PstI fragment from pYS1 replaced with 1240 bp PstI fragment of pUC4K 
containing aph gene, in . nova IFM 10797 
This study 
pYS1K2 1264 bp BamHI fragment of pUC4K containing aph gene inserted into BglII site of 
pYS1, in . nova IFM 10797 
This study 
pYS1K3 1320 bp fragment of pUC4K containing aph gene amplified with primers 
PUC4K10F1 and PUC4K38R1 and inserted into the AgeI site of pYS1, in . nova 
IFM 10797 
This study 
pYS1K4 1252 bp SalI fragment of pUC4K containing aph gene inserted into XhoI site of 
pYS1, in . nova IFM 10797 
This study 
pYSA1 21 bp SacI-XbaI fragment of pUC18 replaced with 2903 bp SacI-XbaI fragment 
from pYS1, in E. coli GM2929 
This study 
pYSA2 1320 bp fragment of pUC4K containing aph gene amplified with primers 
PUC4KFse10F1 and PUC4KFse38R1 and inserted into the FseI site of pYSA1, in 
E. coli GM2929 
This study 
pYS1K5 4231 bp SacI-XbaI fragment from pYSA2 containing aph gene ligated to 1423 bp 
SacI-XbaI fragment from pYS1, in . nova IFM 10797   
This study 
pUC18 General purpose E. coli vector Fermentas 
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p106 E. coli vector containing promoter-less cat gene downstream of a multiple cloning 
site 
Atchison et al., 
1989 
pNVCAT ~1900 bp HpaI-PscI fragment (filled-in) containing cat gene from p106 ligated to 
4016 bp HindIII-PscI fragment (filled-in) of pNV18  
This study 
pNVCATP1 Position 4214-427 of pYS1 amplified with primers PYS1PromF1 and 
PYS1PromR1 and ligated into BamHI site of pNVCAT in orf1 orientation with 
respect to cat  
This study 
pNVCATP2 Position 4214-427 of pYS1 amplified with primers PYS1PromF1 and 
PYS1PromR1 and ligated into BamHI site of pNVCAT in orf3 orientation with 
respect to cat  
This study 
pNVCATP3 Position 4115-539 of pYS1 amplified with primers PYS1PromF2 and 
PYS1PromR2 and ligated into BamHI site of pNVCAT in orf1 orientation with 
respect to cat 
This study 
pNVCATP4 27 bp HindIII-BamHI fragment of pNVCAT replaced with PCR fragment spanning 
positions 3605-427 of pYS1 amplified with primers PYS1ORF3F1 and 
PYS1PromR1, in orf1 orientation with respect to cat 
This study 
pNVCATP5 27 bp HindIII-BamHI fragment of pNVCAT replaced with PCR fragment spanning 
positions 3605-539 of pYS1 amplified with primers PYS1ORF3F1 and 
PYS1PromR2, in orf1 orientation with respect to cat 
This study 
pYS1R1Gyr ~200 bp segment of gyrA from . aobensis IFM 10795 amplified with primers 
GyrAF1 and GyrAR1 and cloned into the HindIII site of pYS1R1 
This study 
pDA71 Rhodococcus-E. coli shuttle vector with an ecoR suicide gene Quan and Dabbs, 
1993 
pFB7 ~1600 bp inhibitory BglII fragment from Rhodococcus phage FND1 DNA cloned 
into pDA71 
Shibayama, 2007 
pFB8 ~2200 bp inhibitory BglII fragment containing a gene resembling those encoding a 
thymidilate synthase complementing protein, from phage FND1 DNA cloned into 
pDA71 
Shibayama, 2007 
pFB10 ~4600 bp inhibitory BglII fragment from phage FND1 DNA cloned into pDA71 Shibayama, 2007 
pFB19 ~3750 bp inhibitory BglII fragment from phage FND1 DNA cloned into pDA71 Shibayama, 2007 
pFP8 ~1600 bp inhibitory PstI fragment containing a gene resembling those encoding a 
phage capsid protein, from phage FND1 DNA cloned into pDA71 
Shibayama, 2007 
pFP14 ~2700 bp inhibitory PstI fragment containing a gene resembling those encoding a 
HNH endonuclease, from phage FND1 cloned into pDA71 
Shibayama, 2007 
pFP16 ~2100 bp inhibitory PstI fragment from phage FND1 DNA cloned into pDA71 Shibayama, 2007 
pPH1 ~2700 bp inhibitory HindIII fragment containing a gene resembling those encoding 
a phage head decoration protein, from Rhodococcus phage PGS1 cloned into 
pDA71 
Shibayama, 2007 
pPH7 ~4600 bp inhibitory HindIII fragment containing a gene resembling those encoding 
an -subunit of DNA polymerase III, from phage PGS1 cloned into pDA71 
Shibayama, 2007 
pOLYG Mycobacterium-E. coli shuttle vector O’Gaora et al., 
1997 
pFBM7 ~1600 bp BglII insert from pFB7 cloned into pOLYG This study 
pFBM8 ~2200 bp BglII insert from pFB8 cloned into pOLYG This study 
pFBM10 ~4600 bp BglII insert from pFB10 cloned into pOLYG This study 
pFBM19 ~3750 bp BglII insert from pFB19 cloned into pOLYG This study 
pFPM8 ~1600 bp PstI insert from pFB8 cloned into pOLYG This study 
pFPM14 ~2700 bp PstI insert from pFP14 cloned into pOLYG This study 
pFPM16 ~2100 bp PstI insert from pFP16 cloned into pOLYG This study 
pPHM7 ~4600 bp HindIII insert from pPH7 cloned into pOLYG This study 
pEcoR251 E. coli vector with ecoR suicide gene Zabeau and 
Stanley, 1982 
pYS13 
 
cI857 cloned into BamHI site of pEcoR251 by shotgun cloning of Sau3AI partial 
digest of λ genome 
This study 
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pYS13* ~900 bp EcoRI-SfuI fragment within ecoR deleted from pYS13 This study 
pYS13-1 
 
cI857 amplified from pYS13 using forward primer containing BamHI site and 
reverse primer containing BglII site and cloned into BamHI site of pEcoR251 
This study 
pYS13-1* ~190 bp BglII-PstI fragment within ecoR from pYS13-1 deleted This study 
pYSM13-1 ~2400 bp EcoR-PscI fragment containing ecoR and cI857 from pYS13-1 ligated to 
~4200 EcoR-PscI backbone of pNV19 
This study 
pYSM13-1* ~2200 bp EcoR-PscI fragment containing deleted ecoR and cI857 from pYS13-1* 
ligated to ~4200 EcoR-PscI backbone of pNV19 
This study 
 
 
2.3 Primers 
All primers, excluding those for site-directed mutagenesis, are listed in Table 2.6. 
Primers for site-directed mutagenesis are listed in Table 2.7.  
 
Table 2.6. Primers 
Name 
Sequence (5'-3') (introduced enzyme site 
underlined) 
Enzyme site 
introduced 
Region amplified 
PYS1Rep48F1 gatcgctagcacatctcggcacattgcccga heI 
PYS1Rep9R1 gatcgctagccgatggggctgaccgttacc heI 
Position 1904-3966 of pYS1 
spanning the SSO, DSO, and 
rep 
PYS1Rep48F1 gatcgctagcacatctcggcacattgcccga heI 
PYS1Rep14R1 gatcgctagctaacggtccaatctccgcta heI 
Position 1904-3597 of pYS1 
spanning the SSO, DSO, and 
rep 
PYS1Rep1990F1 gatctagctagccccgaaacgcactgaggg heI 
PYS1Rep14R1 gatcgctagctaacggtccaatctccgcta heI 
Position 1990-3597 of pYS1 
spanning a portion of SSO, 
DSO, and rep 
PYS1Rep2050F1 gatctagctagccttgcctagccagcacgg heI 
PYS1Rep14R1 gatcgctagctaacggtccaatctccgcta heI 
Position 2050-3597 of pYS1 
spanning a portion of SSO, 
DSO, and rep 
PYS1Rep2100F1 gatctagctagctcgatggtagcaactgcg heI 
PYS1Rep14R1 gatcgctagctaacggtccaatctccgcta heI 
Position 2100-3597 of pYS1 
spanning the DSO and rep 
PYS1Rep54F1 gatcgctagcaatccggacgacctcgccggta heI 
PYS1Rep9R1 gatcgctagccgatggggctgaccgttacc heI 
Position 2182-3966 of pYS1 
spanning the DSO and rep 
PYS1Rep54F1 gatcgctagcaatccggacgacctcgccggta heI 
PYS1Rep14R1 gatcgctagctaacggtccaatctccgcta heI 
Position 2182-3597 of pYS1 
spanning the DSO and rep 
PUC4K10F1 gatcaccggtgctgaggtctgcctcgtgaa AgeI 
PUC4K38R1 gatcaccggtcggctcgtatgttgtgtgga AgeI 
Position 435-1754 of 
pUC4K spanning aph 
PUC4KFse10F1 attataggccggccgctgaggtctgcctcgtgaa FseI 
PUC4KFse38R1 attataggccggcccggctcgtatgttgtgtgga FseI 
Position 435-1754 of 
pUC4K spanning aph 
pYS1PromF1 tgacggatccgtcgtatctccttgcgattc BamHI 
pYS1PromR1 tgacggatcccttgccacgaatcttcgtgt BamHI 
Position 4214-427 of orf3-
orf1 intergenic region of 
pYS1 
PYS1PromF2 tgacggatccaggcccttcctgtgagattc BamHI 
PYS1PromR2 tgacggatccagtgtttctcctggtcagtg BamHI 
Position 4115-539 of orf3-
orf1 intergenic region of 
pYS1 
PYS1ORF3F1 tgatctaagcttgcatgaggtgtgaccctc HindIII 
PYS1PromR1 tgacggatcccttgccacgaatcttcgtgt BamHI 
Position 3605-427 of pYS1 
spanning orf3 and orf3-orf1 
intergenic region 
PYS1ORF3F1 tgatctaagcttgcatgaggtgtgaccctc HindIII 
PYS1PromR2 tgacggatccagtgtttctcctggtcagtg BamHI 
Position 3605-539 of pYS1 
spanning orf3 and orf3-orf1 
intergenic region 
GyrAF1 gtacaagcttgcgcatcgtggtgacggtcaa HindIII 
GyrAR1 gtacaagcttcctggtgcgccggatgatgac HindIII 
~200 bp region of . 
aobensis gyrA, based on . 
farcinica genome sequence 
RtGyrAF gcgcatcgtggtgacggtcaa none 
RtGyrAR cctggtgcgccggatgatgac none 
~200 bp region of . 
aobensis gyrA, based on . 
farcinica genome sequence, 
for real-time PCR 
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RtRep2100F tcgatggtagcaactgcg none 
RtRep2310R ctcctgctaccgcccgct none 
Position 2100-2310, within 
the rep gene of pYS1, for 
real-time PCR 
CI4F1 gtacggatcctcaacacgcacggtgttaga BamHI 
CI41R1 gctaagatcttgccgatcagccaaacgtc BglII 
cI857 with PRM, OR2, and 
OR3 from pYS13 
Some primers above appear more than once when used in combination with different 
primers to amplify different regions. 
 
Table 2.7. Primers for site-directed mutagenesis 
Name 
Sequence (5'-3') (mutated region 
capitalized; introduced enzyme site 
underlined) 
Enzyme site introduced Mutation introduced 
SSOloop2F ggccttcttgcctGCAGagcacgggccgg PstI 
SSOloop2R ggataagccccgagggcgaaccagtgcat none 
agcc of second terminal 
loop of pYS1 SSO 
mutagenized to gcag  
DSOF ggcggggaggccAGATCTcaccccggcgag BglII 
DSOR tccgggcaaacccgcctgcggcgg none 
ttggaa of DSO of pYS1 
mutagenized to agatct 
 
 
2.4 Isolation of bacteriophages 
 
2.4.1 Soil assay 
One gram of soil was incubated in 10 ml of LB broth supplemented with 10 mM 
CaCl2 and 10 mM MgCl2 in a 100 ml flask on a rotary shaker at ~80 rpm overnight at 
30 °C. The soil suspension was centrifuged in a Beckman JA-20 rotor at 15000 rpm 
for 10 min, after which the supernatant was decanted. 2 ml of this supernatant was 
added to 50 µl of a stationary phase culture of M. smegmatis mc2155r, vortexed for 1 
sec, and left at 37 °C for 30 min. Then 2 ml of sloppy agar was added, mixed by 
rolling between the palms, and poured onto an LB agar plate supplemented with 10 
mM CaCl2, 10mM MgCl2, 100 µg/ml rifampicin, and 50 µg/ml nystatin. The plate 
was incubated for ~2 days and checked for plaques. 
 
2.4.2 Production of phage suspensions 
A plaque was picked by stabbing a toothpick through the soft agar and dipping into 
100 µl LB broth. The suspension was vortexed for 1 sec, left for 5 min, and 
microfuged for 3 min. The supernatant containing the phage was collected.  
 
2.4.3 Single plaque purification 
Phage suspension was serially diluted with LB broth. For the last dilution, 10 µl was 
added to 2 ml LB broth and 50 µl stationary phase bacterial culture, vortexed for 1 sec, 
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and left at 30 °C or 37 °C (whichever was the optimum growth temperature for the 
host bacteria) for 30 min. 2 ml sloppy agar was added and poured onto an agar plate 
containing 10 mM CaCl2 and 10mM MgCl2. The plate was incubated at 30 °C or 
37 °C until plaques appeared.  
 
2.5 Phage lysate production 
 
2.5.1 Plate lysate production 
10 µl phage suspension was added to 2 ml LB broth and 50 µl host bacterial culture, 
vortexed for 1 sec, left at 30 °C or 37 °C for 30 min, and overlaid onto an LB agar 
plate containing 10 mM CaCl2 and 10 mM MgCl2. Multiplicity of infection (MOI) 
was adjusted by diluting the phage suspension when necessary. The plate was 
incubated at 30 °C or 37 °C until a significant difference was observable between this 
plate and the no-phage-control plate.   
Onto the plate lysate, 2 ml LB broth was added. The entire top agar layer, together 
with all the liquid, was collected with a spatula and transferred to a centrifuge tube. 
The tube was vortexed for 5 sec, left for 5 min, and centrifuged in a JA-20 rotor at 
15000 rpm for 10 min. The supernatant was collected. When necessary, the lysate was 
supplemented with antibiotics or filter sterilized. 
 
2.5.2 Small scale liquid lysate production 
200 µl phage suspension was added to 250 µl bacterial culture and 10 ml LB broth 
supplemented with 10 mM CaCl2 and 10 mM MgCl2 in a 100 ml flask. MOI was 
adjusted by diluting the phage suspension when necessary. The flask was left at 30 °C 
or 37 °C for 30 min, followed by incubation on a rotary shaker at ~80 rpm until a 
significant difference was observable between this flask and the no-phage-control 
flask. The lysate was centrifuged in a JA-20 rotor at 15000 rpm for 10 min. The 
supernatant was collected. When necessary, the lysate was supplemented with 
antibiotics or filter sterilized. 
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2.5.3 Large scale liquid lysate production 
The condition optimal for the production of 10 ml lysate was applied to the 
production of 500 ml lysate, by appropriately scaling up all components. This was 
done by preparing five 100 ml lysates, each in 1000 ml flasks. 
 
2.6 Phage purification 
To the large scale lysate NaCl was added to a final concentration of 1 M and 
dissolved by slow stirring on a magnetic stirrer. Then polyethylene glycol (PEG 6000) 
was added to a final concentration of 10% (w/v) and again dissolved in the same 
manner. The lysate was cooled in an ice-water slurry for at least 1 hr and centrifuged 
in a JA-10 rotor at 9000 rpm for 20 min at 4°C. The supernatant was discarded, and 
the phage pellet was purified in either a step gradient or equilibrium gradient of CsCl. 
 
2.6.1 Phage purification in a step gradient 
The phage pellet was dissolved in 3.5 ml of SC buffer containing 50% (w/v) CsCl and 
transferred to a Beckman Quick-Seal centrifuge tube using a Pasteur pipette. A step 
gradient was produced by layering 800 µl of CsCl solutions of increasing density 
(1.45, 1.50, 1.70 g/ml) at the bottom of the tube. The tube was centrifuged in a 
Beckman VTi 65.2 rotor at 25000 rpm for 1 hr at 4°C. The bluish band of phage was 
extracted using a needle and a syringe. 
 
2.6.2 Phage purification in an equilibrium gradient 
The phage pellet was resuspended in 5 ml of SC buffer containing 81.7% (w/v) CsCl.  
This was loaded into a Beckman Quick-Seal centrifuge tube and centrifuged at 38000 
rpm for 24 hrs at 4°C. The phage band was extracted using a needle and a syringe. 
 
2.7 D
A preparations 
 
2.7.1 Phage genomic D
A preparation 
 
2.7.1.1 Dialysis of purified phage in CsCl 
Dialysis tubing was prepared according to Sambrook et al., 1989. Tubing of ~10 cm 
lengths were boiled for 10 min in 800 ml of 2% NaHCO3 and 1 mM EDTA (pH 8.0) 
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and rinsed in dH2O. The tubing was then boiled for 10 min in 800 ml of 1 mM EDTA 
(pH 8.0) and rinsed in dH2O. 
150-300 µl of purified phage suspension diluted to 1 ml with dH2O was transferred 
into the dialysis tubing which was then dialyzed for 1 hr against 1000 volumes of a 
buffer containing 10 mM NaCl, 50 mM Tris-HCl (pH 8.0), and 10 mM CaCl2 while 
gently stirring with a magnetic stirrer.  The dialysis sac was then transferred to a fresh 
flask of buffer and dialyzed for another 1 hr. 
 
2.7.1.2 Phage genomic D
A extraction 
To obtain DNA from a plate lysate or purified phage, DNaseI and RNase were added 
to a final concentration of 10 µg/ml and incubated at room temperature for 6 hrs 
before subjecting it to the following steps. To the phage suspension, EDTA (pH 8.0) 
was added to a final concentration of 20 mM, proteinase K to a final concentration of 
50 µg/ml, and SDS to a final concentration of 0.5% (w/v). The mixture was incubated 
at 56°C for 1 hr, cooled to room temperature, subjected to three phenol extractions 
and one chloroform extraction. A salt-ethanol precipitation was performed on the 
phage DNA, which was then dissolved in dH2O or 4 mM Tris-HCl (pH 8.0). 
 
2.7.2 Bacterial bulk total D
A extraction 
A 200 ml culture of E. coli, ocardia, Rhodococcus, Bacillus, or Staphylococcus was 
grown in appropriate media supplemented with retardatory concentration of glycine 
(ocardia spp., 3%; R. erythropolis, 2%; B. subtilis, 1%; S. aureus, 7%; E. coli, no 
glycine necessary). Cells were centrifuged in a Beckman JA-10 rotor at 6000 rpm for 
10 min at room temperature. The pellet was resuspended in 5 ml of TE supplemented 
with lysozyme at a concentration of 5 mg/ml and incubated for >1 hr at 37 °C. A 
minute quantity of proteinase K and a 1/10 volume of 10% TE-SDS were added and 
incubated for >1 hr at 37 °C. The viscous lysate was transferred to a Beckman 50Ti 
tube and spun at 40000 rpm for 30 min. The supernatant was transferred to a JA-20 
tube, to which 4.4 g CsCl was added and dissolved. The tube was centrifuged at 
15000 rpm in a JA-20 rotor for 15 min, after which the supernatant was transferred to 
a clean bottle. 400 µl of 1% ethidium bromide (EtBr) was added, and its refractive 
index was adjusted to between 1.391 and 1.392 using a refractometer. The solution 
was transferred into a Quick-Seal tube and centrifuged at 45000 rpm in a VTi65.2 
rotor for 16 hrs. Under a UV light, the upper band representing chromosomal DNA 
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was extracted with a needle and syringe. Where a lower plasmid band was available 
and required, it was also extracted in a similar manner. EtBr from the extracted DNA 
was removed by butanol extraction, and CsCl was removed by ethanol precipitation. 
 
2.7.3 E. coli bulk plasmid preparation 
A 100 ml culture of E. coli transformant was grown to stationary phase in the 
presence of appropriate antibiotic, after which cells were harvested by centrifugation 
in a JA-10 rotor at 6000 rpm for 10 min. Cells were resuspended in 5 ml of solution I 
and transferred to a JA-20 tube. Then, 10 ml of solution II was added, mixed by 
gentle inversion, and incubated for 15 min at room temperature. Thereafter, 7.5 ml of 
solution III was added, shaken vigorously, and left in an ice-water slurry for 10 min. 
Cellular debris was removed by centrifugation in a pre-cooled (4°C) JA-20 rotor at 
15000 rpm for 10 min. The supernatant was transferred to a clean JA-20 tube, warmed 
to room temperature, to which 12 ml of isopropanol was added and left for 10 min. 
The tube was centrifuged at 15000 rpm for 15 min. The supernatant was decanted, 
after which the pellet was washed with 2 ml of 96% ethanol and vacuum dried for 20 
min. The DNA was resuspended in 4 ml TE for 2 hrs at 30 °C. 400 µl of 1% EtBr and 
4.1 g of CsCl were added, inverted to mix, and the refractive index was adjusted to 
between 1.387 and 1.389 using a refractometer. This was loaded into a Quick-Seal 
tube and centrifuged in a VTi 65.2 rotor at 45000 rpm for 16 hrs. The plasmid band 
was extracted under a UV light using a needle and syringe. EtBr was removed from 
the DNA by butanol extraction, and CsCl was removed by ethanol precipitation.   
 
2.7.4 E. coli plasmid mini preparation 
1 ml cultures of E. coli transformants were grown to stationary phase in the presence 
of appropriate antibiotic. Cells were harvested by microfuging for 30 sec, the 
supernatant decanted, and the pellet resuspended in 80 µl of solution I. 160 µl of 
solution II was mixed in by gentle inversion, left for 10 min, 120 µl of solution III 
added, shaken vigorously, and left in an ice-water slurry for 5 min. Cellular debris 
was removed by microfuging for 5 min at 4°C. The supernatant was transferred to a 
clean microfuge tube and warmed to room temperature. 220 µl isopropanol was added 
and after 10 min at room temperature the tube was microfuged for 5 min, the 
supernatant decanted, then the pellet was washed with 150 µl of 96% ethanol and 
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vacuum desiccated for 20 min. The DNA was dissolved in 100 µl dH2O or 4 mM 
Tris-HCl (pH 8.0) containing 1 µl of 10 µg/ml RNase. 
 
2.7.5 Gram-positive plasmid mini preparation 
A 1 ml culture of ocardia or Mycobacterium grown to stationary phase in the 
presence of retardatory concentration of glycine (ocardia spp., 3%; M. smegmatis, 
0.5%) was microfuged, and the pellet was suspended in 1 ml of resuspension solution 
supplemented with lysozyme at a concentration of 5 mg/ml. Following incubation for 
>3 hrs at 37 °C on a shaker, the cells were collected by microfuging and resuspended 
in 280 µl TE. 280 µl 10% TE-SDS was added and mixed by gentle inversion for 20 
min. 73 µl of 4.5 M sodium acetate (pH 6.0) was added, mixed by gentle inversion, 
and left on ice for 1 hr. The tube was microfuged for 20 min at 4 °C, after which the 
supernatant was collected and purified by phenol-chloroform extraction. The DNA 
was salt-ethanol precipitated, vacuum dried for 20 min, and resuspended in dH2O or 4 
mM Tris-HCl (pH 8.0). 
 
2.7.6 Bacterial plasmid mini preparation using a kit 
For purer plasmid mini preparations, GeneJET Plasmid Miniprep Kit (Fermentas) was 
used. For E. coli, the kit was used according to the manufacturer’s instructions. For 
Gram-positive bacteria, two modifications (Parish and Stoker, 1998) were made. First, 
lysozyme was added to a concentration of 5 mg/ml following resuspension of the cell 
pellet in Resuspension Solution and incubated for >3 hrs at 37 °C on a shaker. Second, 
after passing the cleared lysate through the column, a 1:1 mixture of chloroform-
methanol (250 µl each) was used to wash the column. This was followed by the 
regular washing steps using the Wash Solution provided by the manufacturer. 
 
2.8 D
A manipulations 
 
2.8.1 Butanol extraction 
EtBr was removed from DNA by adding 1/10 volume of butanol, mixing by inversion, 
and microfuging for 10 sec. Upper layer containing EtBr was removed. Extraction 
was repeated ~5 times to remove all traces of EtBr.  
 
 
 48 
2.8.2 Phenol-chloroform extraction 
For DNA volumes of <300 µl, TE buffer was added to make it up to this volume.  
Then, 1/3 volume of TE-saturated phenol was added, mixed by inversion, and 
microfuged for 5 min at room temperature. The aqueous phase was collected, to 
which 1/3 volume of chloroform was added, mixed by inversion, and microfuged for 
30 sec. The aqueous phase was collected, and the DNA was subjected to salt and 
ethanol precipitation.   
 
2.8.3 Salt and ethanol precipitation 
DNA was precipitated by adding 1/10 volume of 1 M NaCl and 2 volumes of 96% 
ethanol. This was mixed by gentle inversion and microfuged for 20 min at 4 °C. The 
supernatant was decanted, and the tube was blotted on paper towel, followed by 
vacuum drying for 20 min. The DNA was resuspended in an appropriate volume of 
dH2O or 4 mM Tris-HCl (pH 8.0).  
 
2.8.4 Restriction digestions 
Restriction endonucleases were obtained from Fermentas, Roche, or New England 
Biolabs and used according to their instructions. An appropriate volume of 10× 
digestion buffer was added to the DNA. For double digestions, a common buffer in 
which both enzymes showed suitable activity was chosen. Then, suitable units of 
enzyme were added and incubated at an appropriate temperature for >3 hrs. When 
necessary, the endonuclease was inactivated by either heat treatment or phenol 
extraction. For enzymes which could be heat-inactivated, the manufacturer’s 
instruction was followed for the correct incubation temperature and time. Otherwise, 
phenol-chloroform extraction was conducted. 
 
2.8.5 Removal of overhangs 
DNA with overhangs was treated with Klenow fragment (Fermentas) to produce blunt 
ends. An appropriate volume of 10× reaction buffer and suitable units of the enzyme 
were added in incubated at 37 °C for 20 min. The enzyme was then heat-inactivated at 
75 °C for 10 min.  
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2.8.6 Detection and digestion of single-stranded D
A 
For the detection and digestion of single-stranded form of plasmids, S1 nuclease 
(Fermentas) was used. In a total reaction volume of 15 µl, ~300 ng of ocardia total 
DNA, 1.5 units of enzyme, and 3 µl of 5× reaction buffer were added. The reaction 
was incubated at room temperature for 30 min, followed by enzyme inactivation by 
adding EDTA to a final concentration of 30 mM and heating at 70 °C for 10 min. The 
digested DNA was run on a gel and examined by Southern analysis. 
 
2.8.7 Dephosphorylation of 5' ends 
FastAP Thermosensitive Alkaline Phosphatase (Fermentas) was used to prevent 
recircularization of vector. An appropriate volume of 10× dephosphorylation buffer 
and suitable units of alkaline phosphatase were added and incubated at 37°C for 20 
min. The enzyme was then heat-inactivated at 75°C for 5 min. 
 
2.8.8 Ligation 
T4 DNA ligase (Fermentas) was used for ligation reactions. For sticky-end and blunt-
end ligations, 5 units and 25 units, respectively, of the enzyme were used. After 
mixing DNA to be ligated, the reaction volume was made up to 20 µl by adding 2 µl 
reaction buffer and appropriate volumes of dH2O and enzyme. For sticky-end 
ligations, reactions were incubated at 22 °C for ≥2 hrs. For blunt-end ligations, 
reactions were incubated overnight. The ligase was then inactivated at 65 °C for 10 
min. 
 
2.8.9 Freeze-squeeze method of D
A purification from agarose gels 
Piece of agarose containing the DNA of interest was placed in a microfuged tube, 
crushed with a spatula, and frozen at -70°C for >2 hrs. The agarose was then 
completely thawed at room temperature, followed by microfuging for 15 min after 
which the supernatant was collected. The pellet was crushed again, and the process 
was repeated. The supernatants from the first and second rounds were pooled and 
subjected to two phenol extractions and one chloroform extraction. The DNA was 
salt-ethanol precipitated, vacuum dried for 20 min, and resuspended in 50 µl of dH2O 
or 4 mM Tris-HCl (pH 8.0). 
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2.8.10 Determination of D
A concentration 
DNA concentration was measured using the NanoDrop ND-1000 Spectrophotometer 
at OD260. DNA purity with respect to protein contamination was assessed by 
measuring OD260/OD280 ratio. Where a suitable solution to blank the reading on the 
spectrophotometer was not available, an alternative method was used. An aliquot of 
the DNA was run on a gel, which was then quantified using the UVP LabWorks 
Image Acquisition and Analysis Software (Ver.4.5) by comparing band intensity 
between the DNA and the molecular weight marker, for which the concentration had 
been predetermined by the manufacturer.  
 
2.9 Gel electrophoresis 
 
2.9.1 Agarose gel electrophoresis 
Agarose stock solutions were prepared in 0.5× TBE buffer at concentrations of 0.4-
1.4% depending on the size of the DNA fragment to be separated. A gel was prepared 
by pouring 30 ml of agarose solution containing 1 µg/ml EtBr into a gel tray inserted 
with a comb, which was then polymerized at 4 °C for 20 min. After removing the 
comb, the tray containing the gel was placed in an electrophoresis unit containing 
0.5× TBE buffer with 1 µg/ml EtBr. After DNA samples were mixed with 
bromophenol blue tracking dye and loaded into the wells, electrophoresis was 
conducted at 80-100 V at room temperature. The gel was viewed and photographed 
using the BioRad Molecular Imager Gel Doc XR system. Molecular weight marker 
used was GeneRuler 1 kb Plus DNA Ladder (Fermentas). 
 
2.9.2 Low gelling agarose gel electrophoresis 
Low gelling agarose of 1% concentration was prepared in 0.5× TBE buffer. EtBr was 
added to a final concentration of 1 µg/ml, and the agarose was poured into a tray 
inserted with a comb and polymerized at 4°C for 20 min. The gel was placed in a pre-
cooled electrophoresis unit containing 0.5× TBE with 1 µg/ml EtBr. After DNA 
samples were mixed with bromophenol blue tracking dye and loaded into the wells, 
electrophoresis was conducted at 75 V at 4°C. Using a scalpel under a UV light, a 
band of interest was excised from the gel, from which the DNA was extracted by 
either phenol-chloroform extraction or freeze-squeeze method. In case of the phenol-
chloroform extraction, the piece of agarose carrying the DNA was melted at 60°C for 
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30 min, followed by three phenol extractions. Between each extraction, 1/15 volume 
of 1 M Tris-HCl (pH 8.0) was added. One chloroform extraction was then conducted, 
followed by precipitation of the DNA. 
 
2.10 Transformation and conjugation 
 
2.10.1 CaCl2-mediated transformation of E. coli 
20 ml of pre-warmed LB containing 0.5% glucose was inoculated with 200 µl of an 
overnight culture of E. coli and incubated at 37°C with vigorous shaking for 1.75 hrs.  
The culture, while still being shaken, was cooled in an ice-water slurry for 5 min and 
centrifuged in a pre-cooled JA-20 rotor at 10000 rpm for 5 min at 4°C. The 
supernatant was decanted, and the pellet was resuspended in 10 ml of pre-cooled 
CaCl2 transformation buffer and placed on ice for 15 min, followed by centrifugation 
at 10000 rpm for 5 min at 4°C. The supernatant was decanted, and the pellet was 
resuspended in 1.3 ml of pre-cooled transformation buffer. The cells were left on ice 
for 2-24 hrs. 
100 µl of competent cells and a suitable volume of plasmid were added together, 
mixed by bubbling air with a pipette, and left on ice for 15 min. They were heat-
shocked at 42 °C for 90 sec, after which 0.5 ml of pre-warmed LB was added and 
incubated at 37°C for 1 hr. The cells were spread on an LB agar plate containing an 
appropriate concentration of antibiotics and incubated at 37 °C overnight. 
 
2.10.2 Actinomycete electroporation 
Actinomycetes were grown to late logarithmic phase in media supplemented with 
retardatory concentration of glycine (ocardia spp., 3%; Mycobacterium spp., 0.5%; 
Rhodococcus spp., 2%; G. rubropertincta, 3%; S. lividans, 0.5%; A. oxydans, 1%). 
Cells were chilled in an ice-water slurry for 20 min and centrifuged in a pre-chilled 
JA-20 rotor at 10000 rpm for 10 min. The pellet was resuspended in electroporation 
buffer and washed twice in the same buffer. 200 µl of cells were mixed with 1-10 µl 
of DNA and transferred into a BioRad 0.2 cm electroporation cuvette. Electroporation 
was conducted using the BioRad Gene Pulser I with the following parameters: voltage 
2.5 kV; capacitance 25 µF; resistance 1000Ω. The cells were transferred to a clean 
bottle to which 2 ml of appropriate growth media was added, followed by incubation 
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at 30 °C or 37 °C for 2 hrs. Transformants were selected by spreading on agar plates 
supplemented with appropriate concentration of antibiotics. 
 
2.10.3 Rhodococcus PEG-mediated transformation 
R. erythropolis SQ1 was grown in 5 ml of LBSG (2% glycine) at 30°C for 2 days.  
Cells from 1 ml of this culture were washed once in 1 ml of B buffer, resuspended in 
1 ml of B buffer containing freshly added lysozyme (5 mg/ml), and incubated at 
37 °C for 1.5 hrs with inversion every 10 min. During the incubation, 2 ml of P buffer 
was prepared. P-PEG buffer was also prepared by UV-sterilizing 0.5 g of 
polyethylene glycol (PEG 6000) for 10 min and dissolving it in 1 ml of P-buffer by 
vigorous vortexing. 
The cells were microfuged for 10 sec, gently washed in 1 ml of B buffer, and 
resuspended in 500 µl of P buffer. 25 µl of the protoplast suspension and 5 µl of 
plasmid were added together, mixed by bubbling air with a pipette, and left for 10 min.  
An equal volume of P-PEG buffer was added, mixed by bubbling, and spotted onto a 
pre-cooled regeneration plate. The plate was incubated at 30°C for 12 hrs, underlaid 
with 250 µl of 4 mg/ml chloramphenicol, and further incubated at 30°C for 5 days. 
 
2.10.4 Conjugation 
. aobensis IFM 10795c transformed with insertion mutants of pYS1 were used as 
donors, and . nova IFM 10797 as recipients. Both donor and recipient cells were 
grown to stationary phase and washed twice in the same media without any selective 
agents. Donor and recipient cells were mixed at a ratio of 3:1 and spotted onto a BHI 
agar plate supplemented with 10 mM MgCl2. After incubation at 37 °C for ~7 days, 
lawn of cells were scraped off the agar plate using a toothpick and suspended 
homogenously in media. Serial dilutions of this cell suspension were spread onto BHI 
agar plates supplemented with 40 µg/ml streptomycin to select for recipient cells, and 
undiluted suspension was spread onto plates supplemented with 40 µg/ml 
streptomycin and 200 µg/ml kanamycin to select for transconjugants. Conjugation 
frequency was calculated as the number of transconjugant/recipient cell. 
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2.11 Polymerase chain reaction (PCR) 
 
2.11.1 Conventional PCR 
PCR was performed with the BioRad MJ Mini Personal Thermocycler. Primers were 
designed using the FastPCR software (PrimerDigital) and were purchased from 
Inqaba Biotec. Reaction mixtures were prepared in a final volume of 50 µl or 20 µl 
and usually contained each dNTP at a concentration of 0.2 mM and each primer at 0.5 
µM. For plasmid and chromosomal templates, ~1 ng and ~100 ng of DNA, 
respectively, were added to the reaction mixture. Taq DNA polymerase (Fermentas) 
was used for reactions that did not require subsequent cloning of amplified DNA. 
When cloning was required, Pfu DNA polymerase (Fermentas) was used. For Taq 
DNA polymerase, reaction buffer containing (NH4)2SO4 was added, and MgCl2 was 
added to a final concentration of 2 mM. For Pfu DNA polymerase, only buffer 
containing MgSO4 was used. For 50 µl and 20 µl reactions, 1.25 U and 0.5 U of 
polymerase, respectively, was added.  
Cycling parameters were as follows: initial denaturation at 95 °C for 1-3 min, 
followed by 25-30 cycles of denaturation at 95 °C for 0.5-2 min, annealing at 55-
72 °C for 2 min, extension at 72 °C for 0.5 min/kb for Taq polymerase and 2 min/kb 
for Pfu polymerase, and then final extension at 72 °C for 5-15 min.  
 
2.11.2 Colony PCR of ocardia 
ocardia colony PCR was conducted at a final reaction volume of 20 µl. Instead of 
any template DNA, a visible amount (1-3 mm in diameter) of a ocardia single 
colony was transferred into the reaction mixture using a clean toothpick immediately 
prior to starting of the reaction. Other conditions and cycling parameters were the 
same as conventional PCR.  
 
2.11.3 Site-directed mutagenesis (inverse PCR) 
Phusion Site Directed Mutagenesis Kit (Finnzymes) was used. Primers incorporating 
desired mutations were manually designed. PCR was carried out as instructed by the 
manufacturer. Following PCR, the reaction mixture was subjected to ligation to 
circularize the amplified plasmid, which was then used to transform E. coli. Plasmids 
from transformants were screened by restriction digestion for the desired mutation. 
The mutation was then verified by sequencing.  
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2.11.4 Real-time PCR 
An absolute quantification method as described by Lee et al. (2006) was attempted 
using the Roche LightCycler 2.0. Reaction kit used was LightCycler FastStart DNA 
Master SYBR Green I (Roche). Only cartridge-purified primers were used. To 
determine plasmid copy number, orf2 of pYS1 was used as the target and gyrA of . 
aobensis as the reference. To generate standard curves plotting plasmid copy number 
against threshold cycle, serial 10-fold dilutions, ranging from 1×104 to 1×108 
copies/µl, of a plasmid containing both genes (pYS1R1Gyr) was used as the template. 
PCR on . aobensis total DNA was then conducted, after which copy number of the 
target was compared to that of the reference to calculate plasmid copy number. 
 
2.12 Southern analysis 
 
2.12.1 Southern blot 
Following agarose gel electrophoresis of DNA and photographing of the gel, the 
DNA was partially depurinated by soaking the gel in 0.25 M HCl for 15 min with 
gentle shaking. The solution was removed, and the gel was rinsed briefly twice in de-
ionized H2O. The DNA was then denatured by soaking the gel in 0.5 N NaOH for 30 
min with gentle shaking. The DNA was transferred onto a Hybond-N 0.45 micron 
nylon membrane (Amersham) using the BioRad Vacuum Blotter Model 785 in 10× 
SSC for 90 min at 5 inches Hg. The membrane was then soaked in 2× SSC for 5 min, 
air-dried, and baked between two sheets of filter paper at 80 °C for 30 min. The 
blotted membrane was now ready for hybridization. 
 
2.12.2 Construction of probe 
Double-stranded, biotin-labelled probe was constructed by PCR. In a reaction using 
plasmid pYS1 as the template and PYS1Rep54F1 and PYS1Rep14R1 as the primers, 
biotin was incorporated into the amplicon by adding each dNTP and biotin-11-dUTP 
(Fermentas) to the following final concentration: dATP, 200 µM; dCTP, 200 µM; 
dGTP, 200 µM; dTTP, 150 µM; biotin-11-dUTP, 50 µM. The amplicon was salt-
ethanol precipitated and resuspended in TE.  
Incorporation of the label was confirmed by performing a dot blot. The probe was 
denatured by boiling for 5 min and immediately chilled on ice for 10 min. Ten-fold 
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serial dilutions, ranging from 1 ng to 10 fg, was spotted onto a nylon membrane (no 
pre-treatment necessary). The membrane was baked at 80 °C for 30 min, and the 
biotin signal was detected as written below. Labelling efficiency was considered 
satisfactory if the 100 fg spot could be viewed with the naked eye. 
 
2.12.3 Southern hybridization 
The blotted membrane was submerged in 5× SSC for 2 min and slipped into a 
hybridization bag. Hybridization solution (20 ml per 100 cm2 of membrane) was 
added into the bag, which was sealed with a heat sealer. The membrane was 
prehybridized by incubation at 68 °C for 1-2 hrs by submerging the bag into a water 
bath. The solution inside the bag was redistributed occasionally by gentle inversion. 
During this incubation, the probe was denatured by boiling for 5 min and immediately 
chilled in an ice-water slurry for 10 min. Following incubation, the hybridization 
solution was discarded completely from the bag and replaced with new hybridization 
solution, to which the denatured probe (0.6 µg/20 ml hybridization solution) was 
added. The bag was sealed and incubated at 68 °C for 6 hrs. The solution inside the 
bag was redistributed occasionally by gentle inversion. Following incubation, the 
hybridization solution was discarded (but stored at -20 °C for repeated future usage), 
and the membrane was washed twice for 5 min each in 2× SSC and 0.1% SDS at 
room temperature, and also twice for 15 min each in 0.1× SSC and 0.1% SDS at 
68 °C. The hybridized membrane was air-dried and was now ready for detection. 
 
2.12.4 Detection of signal 
Biotin Chromogenic Detection Kit (Fermentas) was used. Using streptavidin, with 
strong affinity for biotin, conjugated to alkaline phosphatase which produces an 
insoluble blue precipitate upon cleavage of a chromogenic substrate BCIP-T, bands 
on the hybridized membrane could be detected with the naked eye. 
   
2.13 Chromatography 
 
2.13.1 Thin layer chromatography (TLC) 
To prepare nucleotides for separation by TLC, 10-20 µg of phage DNA was 
denatured by boiling for 10 min and immediately chilling in an ice-water slurry for 10 
min. The denatured DNA was treated with ~0.15 units of nuclease P1 (Sigma) at 
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50 °C for 2 hrs. Nucleoside triphosphates were spotted onto cellulose plates (Merck) 
and run using a solvent containing 3 M ammonium sulphate:1 M sodium 
acetate:isopropanol (40:9:1). 
 
2.13.2 High performance liquid chromatography (HPLC) 
To prepare nucleosides for separation by HPLC, phage DNA was denatured by 
boiling for 10 min and immediately chilling in an ice-water slurry for 10 min. The 
denatured DNA was treated with nuclease P1 (Sigma) at 50 °C for 2 hrs, followed by 
treatment with bacterial alkaline phosphatase (Sigma) at 37 °C for 1 hr. HPLC was 
conducted through a Kanto Chemical LiChroCART 150-4.6 LiChrospher 100 RP-18 
(5µm) column using a Gulliver JASCO PU-987 pump with a Gulliver JASCO HG-
980-31 reader. Solvent contained acetonitrile:20 mM ammonium dihydrogen 
phosphate (1:20). A260 readings were measured for each nucleoside as it was passed 
through the column. 
 
2.14 D
A sequencing and analysis 
All DNA sequencing was conducted by Inqaba Biotec. Sequences were analyzed 
using the following programs and databases. 
 
Finch TV (www.geospiza.com/Products/finchtv.shtml) 
Program for viewing chromatograms. 
 
Genbank (www.ncbi.nlm.nih.gov) 
Database of publicly available nucleic acid and protein sequences. 
 
BLAST (www.ncbi.nlm.nih.gov/BLAST/) 
Program for finding nucleic acid or protein sequence similarities to what is available 
in the public database. 
 
Glimmer (www.ncbi.nlm.nih.gov/genomes/MICROBES/glimmer_3.cgi) 
Program for gene prediction in bacterial DNA. 
 
GeneMark (exon.biology.gatech.edu/) 
Program for gene prediction in bacterial DNA. 
 
FGENESB (linux1.softberry.com/berry.phtml) 
Program for gene prediction in bacterial DNA. 
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BPROM (http://linux1.softberry.com/berry.phtml) 
Program for prediction of bacterial promoters. 
 
NEBCutter (tools.neb.com/NEBcutter2/) 
Program for creating restriction maps. 
 
Merger (emboss.bioinformatics.nl/cgi-bin/emboss/) 
Program for merging two overlapping sequences. 
 
Needle (http://emboss.bioinformatics.nl/cgi-bin/emboss/) 
Program for global pairwise alignment. 
 
Edialign (http://emboss.bioinformatics.nl/cgi-bin/emboss/) 
Program for multiple alignment. 
 
FastPCR (en.bio-soft.net/pcr/FastPCR.html) 
Program for primer design and analysis. 
 
Vector NTi (www.invitrogen.com) 
Program for various general sequence analysis. 
 
Mfold (dinamelt.bioinfo.rpi.edu/) 
Program for prediction of nucleic acid secondary structure. 
 
2.14.1 Accession numbers 
DNA sequences of pYS1 and pYS1R1 have been submitted to Genbank. Their 
accession numbers are GU066867 and HQ585611, respectively. 
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3. RESULTS 
 
3.1 Functional analysis of plasmid pYS1 from ocardia 
 
3.1.1 Detection of small plasmids in ocardia 
Thirty-one clinical strains (Table 2.2) of ocardia were screened for small plasmids 
by gel electrophoresis of their total DNA. Eight plasmids in total were detected (Table 
3.1), which is similar in frequency (26%) to previous reports of 31% (Provost et al., 
1996), 20% (Qasem et al., 1999), and 33% (Kasweck et al., 1981) in other strains of 
ocardia. The smallest plasmid was observed in ocardia aobensis IFM 10795, with 
an estimated size of approximately 4 kb, was named pYS1 and sequenced (Genbank 
accession number GU066867). 
 
Table 3.1. Detection of plasmids in ocardia 
Species  Strain a Estimated plasmid size (kb) b 
. brasiliensis  IFM 10745 17 
  25 
. abscessus  IFM 10765 21 
. nova  IFM 10797 23 
. farcinica IFM 10779 12 
. farcinica IFM 10757 15 
. aobensis IFM 10795 4 
. otitidiscaviarum IFM 10786 >50 
a Of the 31 screened strains, only those in which plasmids were detected are listed. 
b Plasmid were assumed to be in their covalently-closed-circular form whose sizes 
were estimated from gel electrophoresis 
 
3.1.2 Prediction of ORFs in pYS1 
The nucleotide sequence of pYS1 showed it to be a circular molecule of 4326 bp with 
a G+C content of 65.1% containing three ORFs, designated orf1, orf2, and orf3 (Fig. 
3.1).  
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Figure 3.1. Schematic map of pYS1. Predicted ORFs and origins of replication are 
indicated by arrows and boxes, respectively. Some unique restriction sites and their 
positions are shown. 
 
The exact translational start site for orf1 was uncertain, as there were three potential 
start codons in frame at positions 447, 483, and 540, as predicted by Glimmer (v3.02) 
(Delcher et al., 1999), GeneMark (v2.4) (Lukashin and Borodovsky, 1998), and 
FGENESB (www.softberry.com). Although ocardia ribosome binding sites have 
been hardly characterized, studies (Dale and Patiki, 1990; Dellagostin et al., 1995; 
Harth and Horwitz, 1997; Movahedzadeh et al., 1997; Mulder et al., 1997; 
Papavinasasundaram et al., 1997) have revealed those of mycobacteria to be purine-
rich sequences, most of which have been detected 4-9 bp upstream of translational 
start sites. We therefore speculated position 540 to be the most probable candidate for 
orf1 translational start due to the presence of the sequence AGGAGGA, resembling a 
mycobacterial ribosome binding site (Dellagostin et al., 1995), 4 bp upstream of it 
(Table 3.2). Consequently, orf1 spans positions 540 to 1970 and encodes a protein of 
477 amino acids. From sequence similarity, orf1 is related to the transfer proteins of 
conjugative Streptomyces plasmids such as pIJ101 (Kendall et al., 1988) and pSN22 
(Kataoka et al., 1994), as well as the FtsK/SpoIIIE family of proteins (Sherratt at al., 
2010) from various bacteria, which are involved in DNA translocation during cell 
division and sporulation. 
Orf2 of pYS1 also had multiple potential translational start sites, at positions 2073, 
2313, 2505, and 2799 (Table 3.2). Of these, position 2505 has the closest (17 bp) 
upstream sequence of six consecutive purines, GAGAGG, resembling a 
mycobacterial ribosome binding site (Movahedzadeh et al., 1997; 
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Papavinasasundaram et al., 1997). Assuming this position to be its translational start 
site, orf2 spans positions 2505 to 3548 and encodes a protein of 348 amino acids that 
is similar to those responsible for the initiation of rolling-circle replication of plasmids 
belonging to the pIJ101/pJV1 family (Ilyina and Koonin, 1992).   
The protein encoded by orf3 is composed of either 113 or 239 amino acids, as there 
are two potential translational start sites, at positions 4213 and 4114, each of which is 
complemented by a conceivable ribosome binding sequence AAGGAG (Harth and 
Horwitz, 1997) 7 bp away and AGGAAGG (Dale and Patiki, 1990) 4 bp away, 
respectively, in the upstream direction (Table 3.2). In addition to this uncertainty, 
Orf3 sequence had no significant similarity to anything in the database. 
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3.1.3 pYS1 is a rolling-circle-type plasmid 
 
3.1.3.1 Orf2 is a rolling-circle-replication protein 
The resemblance of Orf2 protein of pYS1 to replication initiation proteins of the 
pIJ101/pJV1 family (Ilyina and Koonin, 1992) suggested the likelihood of pYS1 
replicating by a rolling-circle mechanism (Khan, 2005). Multiple alignment of pYS1 Orf2 
amino acid sequence with those of Rep from related plasmids revealed the presence of 
five motifs in Orf2 that are usually conserved among proteins which initiate rolling-circle 
replication (Ilyina and Koonin, 1992; Nakashima and Tamura, 2004) (Fig. 3.2). Motif IV 
is a heavy-metal-binding motif rich in cysteine residues (Brasch and Cohen, 1995; 
Mendiola and de la Cruz, 1992; Nakashima and Tamura, 2004). Motif II has histidine 
residues which bind Mg2+ and Mn2+ (Ilyina and Koonin, 1992). Motif III has a tyrosine 
residue that nicks the leading strand to initiate replication and also forms a covalent link 
to the 5́ end of the nicked DNA (Ilyina and Koonin, 1992). Motif V, also known as the C-
terminal motif, has tyrosine and/or glutamic acid residues which are believed to be 
involved in nucleophilic attack of the newly synthesized leading strand near the 
replication termination site (Billington et al., 1998: Fernandez-Gonzalez et al., 1994; 
Noirot-Gross et al., 1994). 
 
         
Consensus C g X X W X C P v C
pYS1 34 C G R I W L C P V C
pXT107 167 C G R I W L C P V C
pAP1 143 C G S V W A C P V C
pRES1 29 C A N G W L C P V C
pLME108 102 C G S V W A C P V C
pIJ101 25 C G R I W L C P V C
pJV1 43 C G R I W F C P E C
Motif IV
   
X X t X T X r H
72 F I T V T L P H
204 F L T I T L P H
180 M L T L T Q R H
66 M V T F T V R H
139 F M T F T V R H
62 L V T F T A R H
80 V V V L T A R H
Motif I
     
H p H X h X l v X
131 H P H A H I L V F
263 H P H A H I L I L
239 H V H S H V L I I
125 H P H L H V I V C
198 H V H L H V L V F
148 H P H I H A I V L
184 H P H L N L L V F
Motif II
 
         
Consensus X X X Y X X K X Q X
pYS1 189 V A A Y V A K V Q E
pXT107 321 I A A Y V A K V Q E
pAP1 314 I G N Y V S K M Q T
pRES1 184 - - E Y I A K A Q D
pLME108 256 L A R Y L S K A Q F
pIJ101 225 L A E Y I A K T Q D
pJV1 272 L I E Y L T K N Q D
Motif III
   
W X e y E X a X X G r X a i X W s X g L X
239 W W E Y E A A T A G R S A I R W S P G L W
371 W W E Y E Q A T A G R S A I R W S P G L W
366 W K E Y E K A S F G R R A L T W S K G L R
234 W L E Y E K A T K G K S W L R W S P K L -
308 W F E W E K G S R G R R Q I G W S A G L R
289 W H E Y E R A T R G R R A I E W T R Y L R
353 W A Q Y E E A L A G R R A I E W T R G L R
Motif V (C-terminal motif)
 
 
Figure 3.2. Multiple alignment of the pYS1 Orf2 sequence with Rep sequences from 
pXT107 (Xia et al., 2007), pAP1 (Billington et al., 1998), pRES1 (Ishikawa et al., 1996), 
pLME108 (Brede et al., 2005), pIJ101 (Kendall and Cohen, 1988), and pJV1 (Servin-
Gonzalez et al., 1995). Residues with 100% identity are indicated with a black 
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background and those with >70% identity with grey. Numbers indicate positions of the 
first amino acids shown. 
 
3.1.3.2 Prediction of the double- and single-stranded origins of replication 
In addition to the five motifs in their replication proteins, rolling-circle plasmids are 
characterized by the presence of double- and single-stranded origins (DSO and SSO) of 
replication. These cis-acting elements were indeed predicted in the pYS1 sequence, in the 
intergenic region upstream of orf2 on the same strand (Fig. 3.1). As DSOs are usually 
conserved among plasmids of the same family (Khan, 2005), multiple alignment of the 
pYS1 sequence with DSO sequences from related plasmids (Fig. 3.3A) revealed their 
potential counterpart in pYS1, which contained the GG dinucleotide shown in pIJ101 
(Servin-Gonzalez, 1993), pJV1 (Servin-Gonzalez, 1993), and pSN22 (Suzuki et al., 
1997) to be the nick site for Rep to initiate leading strand replication. SSOs, on the other 
hand, are not as well conserved but are characterized by inverted repeats that form 
extensive secondary structures, occurring in proximity to the DSOs (Khan, 2005). The 
pYS1 SSO secondary structure predicted by the mfold program (version 3.2) (Zuker, 
2003) formed a hairpin with two terminal loops (Fig. 3.3B), one of which contained a 
sequence highly similar to a conserved CS-6 sequence TAGCGA (Khan, 2004; Kramer et 
al., 1997), shown to act as a terminator of RNA primer synthesis during lagging strand 
replication (Kramer et al. 1998a; Kramer et al., 1998b).  
 
      A 
* *
pYS1 2343 t t g c c c g g - a g g c g g g g - a g g c c t t - - g g a - a c a c c c
pXT107 296 a g c a g a g g c a a - g g g g g c a g g g c g t c - g g a - a t a g a a
pAP1 2374 g t t g c a g g t a t g c g g a a - a a - - c t t t a g g a - a c a a g g
pAN12 574 g t g - - c g a a a a c t g g a c a g - - c t - - - g g c t a c a c t a
pRE8424 5704 g c g a g c g - - a a g c g g a g c - g - c g t a - - g g t g g g g g a g
pIJ101 1696 a g g c - - - a a a a g c g a a - c a - - c c t t - g g g a - a - a g a a
pJV1 1668 c t g g - c a a a a a g - g g a - c - g - c c t - - a g g t - a a a g g g  
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      B 
 
Figure 3.3. DSO and SSO of pYS1. (A) Multiple alignment of the predicted pYS1 DSO 
with those from related plasmids. The conserved GG dinucleotide, shown to be the 
nicking site for Rep in pIJ101 (Servin-Gonzalez, 1993), pJV1 (Servin-Gonzalez, 1993), 
and pSN22 (Suzuki et al., 1997), is indicated by the stars. Numbers indicate positions of 
the first nucleotides shown. Nucleotides with >70% identity are indicated with a black 
background and those with 70%-60% identity with grey. (B) Secondary structure of the 
SSO as predicted by the mfold program (version 3.2) (Zuker, 2003). Dots indicate a six 
base-pair sequence that is highly similar to a conserved CS-6 sequence TAGCGA in the 
SSO of rolling-circle plasmids (Kramer et al., 1997; Kramer et al., 1998a; Kramer et al., 
1998b), which serves as the terminator of RNA primer synthesis for lagging strand 
replication.  
 
3.1.3.3 Detection of the single-stranded intermediate 
To obtain experimental evidence on the mode of replication of pYS1, a blot of total DNA 
from . aobensis IFM 10795 was exposed to a double-stranded 1400 bp biotinylated 
probe that could hybridize to a sequence within orf2 of the plasmid. A faint band which 
migrated faster than the double stranded plasmid was observed, which was shown to be a 
single-stranded form as the band disappeared upon treatment with S1 nuclease, whose 
activity is specific to single-stranded nucleic acids, prior to gel electrophoresis (Fig. 3.4). 
The presence of single-stranded intermediates being the hallmark of rolling-circle 
replication (Khan, 2005), its detection in pYS1, along with the five motifs in Orf2, and 
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the prediction of DSO and SSO all together serve as strong evidence that the plasmid 
employs this mode of replication. 
 
 
Figure 3.4. Detection of single-stranded intermediate of pYS1 by Southern analysis of 
total DNA from . aobensis IFM 10795. Lane 1, total DNA untreated; lane 2, total DNA 
treated with S1 nuclease. 
 
3.1.4 Predicted DSO and SSO are essential in pYS1 replication  
 
3.1.4.1 DSO mutagenesis 
To investigate the importance of the predicted DSO and SSO, a 2 kb region of pYS1 
incorporating these elements along with orf2 was cloned into the heI site of E. coli 
vector pK18 (Pridmore, 1987), yielding pYS1R1. This hybrid plasmid was then 
transformed into . nova, followed by verification of plasmid maintenance by Southern 
analysis of DNA extracted from the transformants and also by E. coli transformation 
using the extracted DNA. Plasmid pYS1R1 was able to transform . nova at a relatively 
high efficiency (3e6 cfu/µg DNA) and replicate in this host (Fig. 3.5), suggesting that all 
elements essential for replication in ocardia are within the 2 kb region. The sequence 
containing the GG dinucleotide in the predicted DSO in pYS1R1 was then altered from 
TTGGAA to AGATCT by in-vitro mutagenesis. This plasmid, pYS1R1D1, was no 
longer able to be maintained in . nova (Fig. 3.5), showing that the DSO, as expected, is 
essential in the replication process.  
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3.1.4.2 SSO mutagenesis and deletions 
Deletion of the SSO in most rolling-circle plasmids causes instability in replication, 
leading to an accumulation of single-stranded intermediates (Khan, 2005). Plasmid 
replication is not all together abolished, however, probably due to the presence of 
secondary signals for single-strand to double-strand conversion (Khan, 2005). To 
investigate whether this situation applied to pYS1R1, the conserved sequence in the 
second terminal loop of the predicted SSO was modified from TAGCCA to TGCAGA, 
yielding pYS1R1S1. Replication of this construct in ocardia, however, was not affected 
(Fig. 3.5), and no accumulation of single-stranded intermediate of the plasmid could be 
detected as judged by band intensity upon Southern analysis (Fig. 3.6). No phenotypic 
difference could be observed with pYS1R1S1 compared to pYS1R1, suggesting that the 
mutated region is not important for replication. To further investigate whether the 
predicted SSO region is of any importance, plasmids with a series of deletions to this 
region were constructed (Fig. 3.5). This was achieved by amplifying different lengths of 
pYS1 DNA and cloning them into the heI site of pK18, which were then used to 
transform . nova. Initially, constructs pYS1R6 and pYS1R7, both fully missing the SSO, 
were checked for plasmid maintenance in ocardia. Both pYS1R6 and pYS1R7 
transformed . nova at a low efficiency (6e2 and 1e2 cfu/µg DNA, respectively) (Fig. 
3.5), and intact plasmids could not be isolated from these transformants, suggesting that 
the predicted SSO is essential in plasmid maintenance. No accumulation of single-
stranded intermediates could be detected in these transformants either (Fig. 3.6). The 
most probable explanation for these transformants was that the plasmid had integrated 
into the host chromosome, giving them resistance to kanamycin on the selective plates. 
To investigate the extent of deletion the SSO was able to tolerate to allow plasmid 
replication, pYS1R3 (missing the lower stem of the hairpin), pYS1R4 (containing only 
half of the second stem-loop), and pYS1R5 (missing the entire stem-loop but less-so than 
pYS1R6 and pYS1R7) were tested (Fig. 3.5). When the lower stem of the hairpin was 
missing (pYS1R3), high transformation efficiency of . nova and plasmid maintenance 
were both sustained, showing that the missing DNA was expendable for these purposes. 
In pYS1R4, however, high transformation efficiency of . nova and plasmid maintenance 
were both lost. Similar observations were made for pYS1R5. No accumulation of single-
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stranded intermediates was observed in any of these transformants (Fig. 3.6). These 
results confirmed that the predicted SSO is indeed essential for pYS1 replication and that 
it can only tolerate minor changes to its structure as there seems to be no secondary 
signals that can compensate for its deficiency. 
 
Figure 3.5. Effect of DSO and SSO mutations and SSO deletions on pYS1 replication. 
Plasmids were constructed by amplifying the indicated regions of pYS1 using heI-site-
containing primers and cloning them into the heI site of pK18 (Pridmore, 1987). Names 
of constructed plasmids and their efficiencies to transform . nova are indicated in the 
first and the second columns, respectively. Presence or absence of plasmids from these . 
nova transformants is indicated by +/- in the third column. In pYS1R1S1 and pYS1R1D1, 
sequences in the second exposed loop of the predicted SSO and the potential nicking site 
in the predicted DSO, respectively, were modified as indicated by the stars. For the SSO 
deletion experiment, cloned regions differed in the extent to which the SSO was included. 
Position of the SSO is indicated in parentheses on the linear map of pYS1 at the top. For 
pYS1R2, pYS1R3, and pYS1R4, secondary structures of the SSO region predicted by 
mfold (version 3.2) (Zuker, 2003) are shown in the last column. Plasmids pYS1R2 had 
the SSO in its intact form, whereas pYS1R3 had the lower part of the stem missing and 
therefore a shorter hairpin. Plasmid pYS1R4 had most of the SSO missing. 
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Figure 3.6. Southern analysis of constructs with mutated DSO or SSO, or deleted SSO. 
Lane 1, pYS1R1; lane 2, pYS1R1S1; lane 3, pYS1R1D1; lane 4, pYS1R3; lane 5, 
pYS1R4; lane 6, pYS1R5; lane 7, pYS1R6; lane 8, pYS1R7. 
 
3.1.5 ocardia-E. coli shuttle vector pYS1R1  
The minimal replicon of pYS1 was revealed in the above experiment to be within a 2 kb 
region containing orf2, DSO, and SSO. As pYS1R1 (Fig. 3.5 and Fig. 3.7) included all 
three elements and was stably maintained in both ocardia and E. coli, this plasmid 
serves as a ocardia – E. coli shuttle vector. Further manipulations, such as increasing 
the number of unique cloning sites, may be made to improve its utility.  
 
 
Figure 3.7. Schematic map of pYS1R1, which was constructed by ligating a 2063 bp 
region of pYS1 containing the rep (orf2), DSO, and SSO into the heI site of E. coli 
vector pK18. 
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3.1.6 pYS1 replicon is compatible with p
V18/19  
Although a few ocardia-E. coli shuttle vectors have been described previously (Yao et 
al., 1994; Liu et al., 2000), plasmid pNV18/19 (Chiba et al., 2007), to our knowledge, 
has been the most useful. To check whether the pYS1 replicon is compatible with 
pNV18/19, which uses a replicon from a mycobacterial plasmid pAL5000 (Stolt and 
Stoker, 1998), . aobensis IFM 10795 was transformed with pNV19. Stable coexistence 
of the two plasmids was confirmed, as a band corresponding to each plasmid was 
detected from a transformant by gel electrophoresis (Fig. 3.8). This could be a useful 
feature of the pYS1 replicon in experiments requiring introduction of two separate 
plasmids into ocardia. 
 
 
Figure 3.8. Gel electrophoresis of a plasmid extraction from . aobensis IFM 10795 
transformed with pNV19 (Chiba et al., 2007). Lane 1, molecular weight marker; lane2, 
XbaI digest, which produced co-migrating bands of two linearized plasmids; lane 3, PstI 
digest, which linearized pNV19 (upper band) and reduced the size of the major pYS1 
band (lower band).  
 
3.1.7 pYS1 copy number   
Real-time PCR, due to its sensitivity, is becoming an increasingly popular method for 
determination of plasmid copy number (Lee et al., 2006; Werbowy et al., 2009).  With 
this method, copy number is calculated as a ratio of frequency of a certain DNA sequence 
(target) in a plasmid to that which occurs as a single copy (reference) in chromosomal 
DNA. Initially, real-time PCR was attempted by using rep as the target gene and gyrA, 
encoding for the α-subunit of the gyrase, as the reference gene. Primers for gyrA were 
designed according to its sequence in the . farcinica genome (Ishikawa et al., 2004), as 
the . aobensis genome has not been sequenced. However, its amplification from the . 
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aobensis genome caused several unspecific bands to appear following conventional PCR, 
which translated to numerous unspecific peaks during melting-curve analysis in real-time 
PCR (data not shown). An alternative method that does not rely on the host genome 
sequence, therefore, was selected.   
By comparing plasmid and chromosomal DNA peak area values (Pushnova et al., 2000) 
after gel electrophoresis of total DNA (Fig. 3.9 and Table 3.3) from . aobensis IFM 
10795 at late logarithmic phase, copy number of pYS1 was estimated under the 
assumption that the genome size of the host is the same as that for . farcinica IFM 
10152 (6,292,345 bp) (Ishikawa et al., 2004). Copy number values obtained from 
experiments conducted in triplicate were 13, 7, and 10. Consequently, the average copy 
number was 10, with a standard deviation of 3. 
 
 
Figure 3.9. Gel electrophoresis of serial dilutions of total DNA from . aobensis IFM 
10795 (left) and a representative area quantitation report (right). Dilutions of DNA run on 
each lane are indicated above the gel. Chromosomal and plasmid bands are indicated. 
Area quantitation report was generated using Quantity One software (version 4.6.7) (Bio-
Rad) after subtraction of background fluorescence. For estimation of plasmid copy 
number, such a report was generated for every single lane of the gel. 
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Table 3.3. Plasmid copy number calculation form 
Dilution (fold) 1 2 4 8 16 32 64 128 256 
          
Chromosomal 
DNA area a 
36500 29400 28000 19300 113300 5490 2580 964 528 
Adjusted area b 36500 58800 112000 154400 212800 175680 165120 123392 135168 
% Difference c  61% 90% 38% 38% -17% -6% -25% 9.5% 
Data used d      175680 165120   
          
Chromosomal 
Average 
170400         
          
Plasmid DNA 
area e 
1440 335 371 185 100     
Adjusted area f 1440 670 1484 1480 1600     
% Difference g  -53% 121% -0.3% 8.1%     
Data used h    1480 1600     
          
Plasmid Average 1540         
          
Plasmid copy 
number i 
13         
a,e For each dilution, chromosomal and plasmid peak area values were obtained using 
Quantity One software (v4.6.7) (Bio-Rad).  
b,f Adjusted areas were calculated by multiplying the area value by the appropriate 
dilution factor.  
c,g % difference was calculated by the following formula:  
 
d,h Only where the % difference was between -20% and 20%, the adjusted area values 
were used to calculate the average value, as they best reflected the amount of DNA 
present.  
i Plasmid copy number was calculated using the following formula: 
 
 
3.1.8 Construction of insertion mutants of orf1, orf3, and the surrounding regions  
To investigate the functions of orf1, orf3, and the flanking intergenic regions, insertion 
mutants of pYS1 were constructed where an aminoglycoside-3́́ phosphotransferase (aph) 
gene was separately inserted into five different sites (Fig. 3.10A). Two of these were in 
orf1 (for pYS1K1 and pYS1K4), one in orf3 (for pYS1K3), one in the intergenic region 
between orf2 and orf3 (for pYS1K5), and one in the intergenic region between orf3 and 
orf1 (for pYS1K2). For pYS1K1, the 304 bp PstI fragment of pYS1 was replaced with an 
aph gene. Construction of pYS1K5 involved insertion at the FseI site. This site, however, 
was resistant to digestion by FseI, an enzyme produced by Frankia species that 
recognizes the sequence GGCCGGCC. When a region containing this restriction site was 
amplified by PCR, however, the amplicon was successfully digested by FseI, suggesting 
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presence of modification on pYS1 DNA preventing enzyme activity. Although this 
restriction enzyme is known to be blocked by overlapping Dcm methylation (New 
England Biolabs, 2009), which recognizes the sequence CCWGG, the closest such 
sequence was found 60 bp away from the restriction site. There is no previous report of 
Dcm methylation blocking restriction at such a distance. It is therefore possible that the 
blockage is due to another modification, which has not been characterized, that 
recognizes a sequence within or overlapping the FseI site. To construct pYS1K5 (Fig. 
3.10B), 2903 bp SacI-XbaI fragment containing the FseI site was first cloned into pUC18 
in E. coli, thereby yielding pYSA1 (Fig. 3.10B). Only when this construct was cloned in 
E. coli strain of GM2929, incapable of Dam and Dcm methylation, was the site digested 
by FseI. An aph gene was then inserted into this site, yielding pYSA2 (Fig. 3.10B), 
followed by removal of the region originating from pUC18 and ligation with the missing 
region of pYS1, the 1423 bp SacI-XbaI fragment. Construction of pYS1K3 involved 
insertion of aph gene at the AgeI site, which lies within the C-terminus of orf3. When this 
site was disrupted, the only plasmid obtainable was spontaneously deleted in orf1 (see 
section 3.1.11.3). 
 
A 
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Figure 3.10. Construction of insertion mutants. (A) Locations of insertions. Restriction 
sites pointed by the arrows are those used for the construction of plasmids pYS1K1, 
pYS1K2, pYS1K3, pYS1K4, and pYS1K5. In case of pYS1K1, the 304 bp PstI fragment 
was replaced with the aph gene. In all other cases, the aph gene was inserted into the 
respective restriction sites. Insertion into the AgeI site, located within the C-terminus of 
orf3, correlated with spontaneous deletion of orf1. (B) Construction of pYS1K5. As the 
FseI site was resistant to digestion by FseI, the region containing this site was first cloned 
into pUC18 in E. coli GM2929, followed by insertion of the aph gene and ligation with 
the rest of DNA from pYS1. 
 
3.1.9 pYS1 replicon is broad-host-range  
Using pYS1K1 and pYS1K2, ten different species from four genera were successfully 
transformed to give a kanamycin resistance phenotype (Table 3.4). Plasmid of 
indistinguishable size could be detected in each of these transformants (data not shown). 
The replicon of pYS1 is therefore broad-host-range. 
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Table 3.4. Host range of the pYS1 replicon 
Species and Strain 
Transformation Efficiency a 
(cfu/µg DNA) 
ocardia aobensis IFM 10795 3e2 
ocardia aobensis IFM 10795c 5e4 
ocardia nova IFM 10797 4e5 
ocardia brasiliensis IFM 10745 1e5 
ocardia farcinica IFM 10757 1e5 
Mycobacterium smegmatis mc2155 4e5 
Mycobacterium parafortuitum 490 4e4 
Gordonia rubropertincta ATCC 25593 1e3 
Rhodococcus erythropolis ATCC 4277 2e5 
Rhodococcus rhodochrous 01 5e6 
Rhodococcus equi ATCC 14887 1e5 
Arthrobacter oxydans C7 < 3e1 
Streptomyces lividans TK23 < 3e1 
Escherichia coli MM294 < 3e1 
a Transformation efficiency is the average between those for pYS1K1 and pYS1K2, as 
similar values were observed for both. Average values from three independent 
transformation experiments are listed. Where the transformation efficiency is < 3e1, no 
single transformant was observed using 33 ng of plasmid DNA. 
 
3.1.10 Curing of . aobensis IFM 10795  
After 90 generations, . aobensis IFM 10795 stably harboured pYS1 as judged by band 
intensity following gel electrophoresis of plasmid extractions from this strain (Figure 
3.11). 
 
Figure 3.11. Gel electrophoresis of total DNA from . aobensis IFM 10795 at 
generations 1, 30, 60, and 90.  
 
To cure the strain of the plasmid, growth-retardatory concentrations of ethidium bromide 
(256 µg/ml) or mitomycin C (0.2 µg/ml) were first tested. These concentrations were 
empirically determined by growing the cells in series of concentrations. Following 
growth in media containing each of these potential curing agents, none of 20 screened 
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colonies had lost the plasmid. We therefore attempted using pYS1K2 as a competitor to 
pYS1 (Fig. 3.12). IFM 10795 was first transformed with pYS1K2, followed by growth of 
the transformant in the presence of kanamycin for 30 generations. Except for the presence 
of the aph gene in pYS1K2, both plasmids were identical and therefore should not have 
been compatible to one another. As kanamycin should have forced pYS1K2 to remain in 
the cell, pYS1 was lost either at the point of transformation or during growth in the 
presence of the antibiotic. The resulting cell, which then only harboured pYS1K2, was 
then grown in the absence of kanamycin for 30 generations, leading to loss of this 
plasmid as well. Of ten colonies screened, three had lost both pYS1 and pYS1K2, as no 
plasmid could be detected by both Southern hybridization and PCR (Fig. 3.13). Moreover, 
transformation efficiency of the cured strain, IFM 10795c, increased by two orders of 
magnitude as compared to the original strain when transformed with pYS1K1 or pYS1K2 
(Table 3.4), confirming absence of a resident plasmid that would otherwise compete with 
the incoming plasmid. However, the relative ease at which pYS1K2 was lost from the 
cell in the absence of a selective marker should be noted, as this is in contradiction with 
the stability of pYS1. The site of aph gene insertion in pYS1K2 was the BglII site in the 
intergenic region between orf3 and orf1, which may therefore contain an element 
contributing to pYS1 stability. 
 
 
Figure 3.12. Process of curing using a competitor plasmid. 
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 A         B 
   
Figure 3.13. Verification of plasmid loss from the cured strain. (A) Southern analysis of 
total DNA using a biotinylated probe hybridizing to a 1.3 kb region of orf2. Lane 1, IFM 
10795; lane 2, IFM 10795c. (B) Gel electrophoresis of colony PCR to amplify a 1.3 kb 
region of orf2. Lane 1, IFM 10795; lane 2, IFM 10795c; lane 3, no colony control. 
 
3.1.11 Analysis of orf3-orf1 pair  
 
3.1.11.1 orf1 is involved in stability 
When various species were transformed with pYS1K1 (disrupted in orf1) or pYS1K2 
(disrupted in the orf3-orf1 intergenic region), it took significantly longer for 
transformants of pYS1K1 to grow up than those of pYS1K2 (Table 3.5). This observation 
was made in eight out of the eleven transformed species, with the greatest difference in 
time observed for . farcinica IFM 10757, which took 76% longer for pYS1K1 
transformants to become visible on selective plates. However, both groups of 
transformants streaked onto fresh media grew at the same rate (data not shown), leading 
to a speculation that orf1 may play a role in pYS1 stability only when the plasmid is 
establishing itself in new hosts.  
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Table 3.5. Differences in time taken for transformants of pYS1K1 and pYS1K2 to appear 
Hrs taken for transformants to appear b 
Species and Strain pYS1K1 
(orf1-disrupted) 
pYS1K2 
(orf1-non-disrupted) 
. aobensis IFM 10795 116 116 
. aobensis IFM 10795c 112 112 
. nova IFM 10797 67 67 
. brasiliensis IFM 10745 ND ND 
. farcinica IFM 10757 37 21 
Mycobacterium smegmatis mc2155 66 55 
Mycobacterium parafortuitum 490 181 118 
Gordonia rubropertincta ATCC 25593 57 42 
Rhodococcus erythropolis ATCC 4277 52 32 
Rhodococcus rhodochrous 01 46 38 
Rhodococcus equi ATCC 14887 70 43 
b These columns show the number of hours taken for pYSK1 and pYS1K2 transformants 
to become visible on selective agar plates. Average values from three independent 
transformation experiments are listed.  
ND, number of hours not determined.  
 
3.1.11.2 Orf1 does not mediate pYS1 transfer 
The similarity of the Orf1 sequence to those of plasmid transfer proteins such as Tra of 
pIJ101 (Kendall and Cohen, 1988) or TraB of pSN22 (Kosono et al., 1996) suggested the 
possibility of its involvement in conjugation. These sequences also fell into the same 
group as the FtsK/SpoIIIE family proteins (Sherratt et al., 2010), which are involved in 
DNA translocation during cell division and sporulation. A multiple alignment of Orf1 
amino acid sequence with related sequences revealed the presence of Walker type A and 
B motifs (Walker et al., 1982) (Fig. 3.14), both of which have been shown in pSN22 to 
be essential in plasmid transfer (Kosono et al., 1996).  
 
 
Figure 3.14. Multiple alignment of pYS1 Orf3 amino acid sequence with those from the 
transfer proteins of pIJ101 (Kendall and Cohen, 1988) and pSN22 (Kosono et al., 1996), 
FtsK from E. coli (Begg et al., 1995), and SpoIIIE from B. subtilis (Wu et al., 1995). 
Walker type-A and B motifs (Walker et al., 1982) are shown. Numbers indicate positions 
of the first amino acid residue shown. Residues with 100% identity are indicated with a 
black background whereas those with 80% in grey. 
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To investigate whether orf1 played a role in pYS1 transfer, . aobensis IFM 10795c 
transformed separately with the five insertion mutants of pYS1 were used as donors and 
. nova IFM 10797 as recipients in a mating experiment. All insertion mutants were 
transferred at a similar frequency of ~5e-4 (transconjugant per recipient), suggesting lack 
of involvement of orf1 in conjugation. 
 
3.1.11.3 orf3-orf1 intergenic region has promoter activity which is controlled by a 
transcriptional repressor encoded by orf3  
As mentioned, the only plasmid that could be obtained following insertion of aph at the 
AgeI site (within orf3) of pYS1, was one that was spontaneously deleted in orf1 (Fig. 
3.15), suggesting a lethal function of orf1 that is suppressed by orf3. This observation 
was in line with the sequence similarity of Orf1 to Tra of pIJ101 (Kendall and Cohen, 
1988) or TraB of pSN22 (Kataoka et al., 1994), which are lethal to the host unless 
negatively regulated by Gnt-R type transcriptional repressors KorA (pIJ101) or TraR 
(pSN22). Genes encoding these repressors occur just upstream to the lethal genes, 
separated by a short intergenic region, and are transcribed in the opposite orientation (Fig. 
3.15). Although orf3 bore no sequence similarity to these transcriptional repressors, its 
location and direction with respect to orf1, in addition to its potential involvement in “kil-
override” (Stein et al., 1989), presented a similar situation as those Streptomyces 
plasmids. 
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Figure 3.15. Similarity of pYS1 to pIJ101. In pYS1, insertion of aph into the AgeI site 
correlated with spontaneous deletion of the region shown in orange. Sequence identities 
of proteins encoded by the respective genes in the two plasmids are indicated. The 
nucleotide positions of pYS1 on this map are different from those in previous figures, as 
orf3 and orf1 needed to be shown as a continuous unit. The two maps are not to scale. 
 
To investigate whether orf3 encoded a novel transcriptional repressor, a reporter assay 
vector pNVCAT (Fig. 3.16A) was constructed, which bears a multiple cloning site 
upstream of a promoter-less chloramphenicol acetyl-transferase (cat) gene in a pNV18 
backbone. In a phenotypic CAT-assay, promoter activity of DNA inserted upstream of 
the cat gene was measured by observing for increase in MIC of chloramphenicol for . 
nova IFM 10797 transformed with constructs depicted in Figure 3.16B. First, the 
intergenic region between orf3 and orf1 was inserted in both orientations. Two different 
lengths of this region were inserted – one between positions 4214 and 426 and another 
between positions 4115 and 539. For the latter, due to reason which could not be 
determined, the fragment could be cloned in E. coli only in the orientation allowing 
testing of promoter activity towards orf1, thus preventing testing of that towards orf3. 
Insertion of these DNA in orf1 orientation resulted in increase in MIC for . nova from 
42 µg/ml (pNVCAT only) to 126 µg/ml (pNVCATP1) and 140 µg/ml (pNVCATP3) (Fig. 
3.16B), suggesting promoter activity towards orf1. In the orf3 orientation (pNVCATP2), 
however, no significant increase in MIC was observed. To investigate whether the 
presence of orf3 reduced the promoter activity detected above, the open reading frame 
was inserted together with the intergenic region as a single unit upstream of the cat gene 
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(pNVCATP4 and pNVCATP5), such that the organization of orf3 with respect to cat was 
identical to that of orf3 with respect to orf1 in pYS1 (Fig. 3.16B). The presence of orf3 in 
these constructs led to a reduction in MIC to 76 µg/ml (pNVCATP4) and 77 µg/ml 
(pNVCATP5). It should be noted that these reduced values were higher than that for 
pNVCAT alone, suggesting some level of promoter activity. Because it was presumed 
that orf3 suppressed orf1 lethality, and its presence in the above constructs led to a 
reduction in promoter activity, it is rational to conclude that its encoded product acts as a 
transcriptional repressor that negatively regulates promoter activity detected in the orf3-
orf1 intergenic region. 
 
 
 
A 
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Figure 3.16. Phenotypic CAT-assay in ocardia by using the reporter assay vector 
pNVCAT. (A) Construction of pNVCAT and its schematic map. A 1.9 kb PscI-HpaI 
fragment from p106 (Atchison et al., 1989), which contained a promoter-less cat gene 
downstream of a multiple cloning site, and a 4 kb HindIII-PscI fragment from pNV18 
(Chiba et al., 2007) were both filled-in and ligated to form pNVCAT. (B) Phenotypic 
CAT-assay to detect promoter activity in the orf3-orf1 intergenic region and reduction of 
promoter activity in the presence of orf3. Parts of pYS1 as indicated were inserted 
upstream of the promoter-less cat gene in pNVCAT, and MIC of chloramphenicol (Cm) 
for . nova transformed with these constructs are shown. Region of pYS1 containing orf3 
and orf1 is shown at the top, with the intergenic regions in black lines. Below pYS1 is 
pNVCAT, in grey, in which nothing is inserted upstream of cat. In pNVCATP1, 
pNVCATP2, and pNVCATP3, the orf3-orf1 intergenic region from pYS1 was inserted in 
the BamHI site upstream of cat. The inserted DNA, whose orientations can be deduced 
from the position of the BglII site, is shown in black in these constructs. Plasmid 
pNVCATP1 contains the pYS1 orf3-orf1 intergenic region in orf1 orientation with 
respect to cat, whereas plasmid pNVCATP2 has the exact same region in orf3 orientation. 
Plasmid pNVCATP3 is similar to pNVCATP1, except it has a longer section of the pYS1 
orf3-orf1 intergenic region towards orf1 and the N-terminus of orf3. In plasmids 
pNVCATP4 and pNVCATP5, a larger section from pYS1 spanning the entire orf3 gene 
and the orf3-orf1 intergenic region was inserted upstream of cat such that the orientation 
of this section with respect to cat was identical to that with respect to orf1 in pYS1. 
Plasmid pNVCATP5 contained a longer section of the orf3-orf1 intergenic region 
towards orf1 than pNVCATP4. 
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3.2 Construction of an inducible expression system for the analysis of antimicrobial 
genes from Rhodococcus phages 
 
3.2.1 Testing of antimicrobial D
A from Rhodococcus phages on Mycobacterium 
In my previous study (Shibayama, 2007), plasmid clones from genomic libraries of 
Rhodococcus phages FND1 and PGS1 were screened for inhibitory activity in R. 
erythropolis. In nine inhibitory clones that were analyzed, 18 ORFs were detected, of 
which 13 had no sequence similarity match to anything in the database, suggesting a huge 
pool of novel antibacterial mechanisms (Shibayama, 2007). As Mycobacterium is the 
actinomycete against which new antimicrobials are most urgently needed (Cox et al., 
2010), those phage DNA were re-cloned into a mycobacterial vector pOLYG (O’Gaora et 
al., 1997) and screened for inhibitory activity in M. smegmatis (Table 3.6). Of the nine 
clones, five had transformation efficiencies of at least two orders of magnitude less than 
the vector-only control. To further study the inhibition exerted by these clones, 
construction of an inducible expression system in Mycobacterium was attempted.    
 
Table 3.6. Inhibitory activity of Rhodococcus phage DNA towards M. smegmatis 
 Transformation efficiency 
(transformants × 104/µg DNA) 
 
 
Transformation efficiency 
(transformants × 104/µg DNA) 
Clone R. erythropolis SQ1 a Clone M. smegmatis mc2155 
pFB7 0.02 pFBM7 <0.002 
pFB8 <0.002 pFBM8 0.64 
pFB10 <0.002 pFBM10 0.003 
pFB19 <0.002 pFBM19 0.067 
pFP8 0.006 pFPM8 0.6 
pFP14 <0.002 pFPM14 0.008 
pFP16 0.006 pFPM16 0.053 
pPH1 0.004 NC ND 
pPH7 0.009 pPHM7 7.9 
pDA71 only  2.6 pOLG only 16 
a Inhibitory activity towards R. erythropolis was determined by Shibayama (2007). 
Clones in the same row have the same insert DNA in different vectors (pDA71 or 
pOLYG). NC, not constructed; ND, not determined. 
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3.2.2 Temperature-inducible expression system in E. coli using the λ switch  
 
3.2.2.1 Construction of a heat-inducible expression system in E. coli 
Plasmid pEcoR251 (Zabeau and Stanley, 1982) (Fig. 3.19) is an E. coli vector with a 
suicide gene encoding the restriction endonuclease EcoRI, whose expression is driven off 
a λ promoter PR. Binding of a λ-encoded cI repressor to two operators, OR1 and OR2, 
adjacent to the PR prevents the association of the RNA polymerase with the promoter, 
thereby repressing transcription (Ptashne, 2004). Although the suicide gene was meant to 
allow the positive selection of transformants with recombinant plasmids (Zabeau and 
Stanley, 1982), it could be also used as a model lethal gene for constructing an effective 
switch.  To utilize the λ switch, the gene encoding a temperature-sensitive mutant of the 
repressor, cI857 (Sussman and Jacob, 1962), was cloned into pEcoR251. This was 
achieved by shotgun cloning a Sau3AI partial-digest of λ (cI857) DNA into the unique 
BamHI site of pEcoR251 in E. coli at 30 °C. As the suicide gene of the vector should kill 
all transformants except where the cI857 gene was successfully ligated into the vector, 
any transformant appearing on the selective plate was likely to be the desired clone. 
Fifteen transformants that grew on the selective plate were tested for growth at both 
permissive (30 °C) and non-permissive (42 °C) temperatures. Plasmid from a clone 
which grew at only the permissive temperature and had the shortest insert (~1.4 kb) was 
named pYS13 (Fig. 3.19). Sequencing of the insert confirmed the presence of the cI857 
gene. A deletion mutant pYS13* (Fig. 3.19), which was no longer lethal to the host, was 
also constructed by removing the ~900 bp EcoRI-SfuI fragment containing most of the 
ecoR. 
 
 84 
 
Figure. 3.17. Construction of pYS13 and pYS13*. 
 
3.2.2.2 Survival curve studies using pYS13 
Studies on inhibitory genes require a tight switch that would keep background 
transcription levels to a minimum and would allow a rapid increase in transcription under 
controlled situations. Using the ecoR as a model bactericidal gene, its inducibility in 
pYS13 was assessed in a survival curve study (Fig. 3.20), whereby the temperature of a 
culture of E. coli harbouring pYS13 was transferred from 30 °C to 42 °C at late 
logarithmic phase, during which colony forming units were measured every 30 minutes. 
At 4 hours after heat-induction, cell count decreased by more than five orders of 
magnitude, suggesting that this switch could tightly repress the transcription of a lethal 
gene and its expression could be induced effectively upon heat-induction. 
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Figure 3.18. Phenotypic assay for heat-induction of ecoR expression in E. coli 
MM294::pYS13. The culture was transferred from 30 °C to 42 °C at 1.5 hrs. The values 
are from three independent assays. 
 
3.2.2.3 Construction and analysis of pYS13-1 
Because pYS13 was constructed by randomly ligating a Sau3AI partial-digest of λ DNA 
into pEcoR251, the piece of phage DNA containing cI857 had extra regions with 
undesirable regulatory elements (Fig. 3.21A). The entire intergenic region upstream of 
cI857 and the N-terminus of cro was present in pYS13, although the only necessary 
element for the expression of cI857 should have been the PRM promoter. Operator OR3 
may have been of additional benefit as it should negatively regulate cI857 transcription 
when its cellular concentration is high (Ptashne, 2004). Because the region containing PR, 
OR1, OR2, and the N-terminus of cro, as well as the downstream region of cI857, seemed 
unnecessary, a plasmid incorporating only the minimum necessary region containing PRM, 
OR3, and cI857 was reconstructed. This was achieved by amplifying this region (~770 
bp) from pYS13 and ligating into the unique BamHI site of pEcoR251. A BamHI site was 
incorporated into the forward primer and a BglII site into the reverse primer used for 
amplification, such that the unique BamHI site was maintained upstream of cI857 after 
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ligation into pEcoR251, which will allow for insertion of additional regulatory elements 
in the future. The new plasmid was named pYS13-1 (Fig. 3.21B). To construct a non-
lethal version of the plasmid, pYS13-1* (Fig. 3.21B), the ~190 bp BglII-PstI fragment 
from within ecoR was removed. 
To test the switch in pYS13-1, a survival curve study was conducted (Fig. 3.22). A 
reduction in cell count of approximately five orders of magnitude was achieved, showing 
that this plasmid contains necessary elements to effectively induce the expression of ecoR. 
 
A 
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Figure 3.19.  Construction of pYS13-1. (A) Organization of PR, PRM, OR1, OR2, and OR3 
in the λ genome, pYS13, and pYS13-1. The length of the ORFs are not to scale to the 
intergenic regions. (B) Schematic map of pYS13-1 and pYS13-1*. 
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Figure 3.20. Phenotypic assay for heat-induction of ecoR expression in E. coli 
MM294::pYS13-1. The culture was transferred from 30 °C to 42 °C at 1.5 hrs. The 
values are from three independent assays. 
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3.2.3 Construction and analysis of a heat-inducible expression system in M. 
smegmatis 
To test the effectiveness of the above heat-inducible λ switch in Mycobacterium, it was 
first necessary to transfer the components that make up the switch from pYS13-1 into a 
mycobacterial replicon. This was done by ligating the ~2400 bp EcoRI-PscI fragment 
containing ecoR and cI857 from pYS13-1 to the backbone of pNV19, the ~4200 bp 
EcoRI-PscI fragment (Fig. 3.23). Similar treatment was made for pYS13-1*.  The newly 
constructed plasmids were respectively named pYSM13-1 and pYSM13-1*.  
 
 
Figure 3.21. Construction of pYSM13-1 and pYSM13-1*. 
 
The temperature-sensitive switch was first tested in Mycobacterium on agar plates. M. 
smegmatis mc2155 transformants of pYSM13-1 only grew at 30 °C while transformants 
of pYSM13-1* grew at both 30 °C and 42 °C, suggesting that both ecoR and cI857 were 
functional in this organism under these conditions. The switch was then tested in broth by 
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a survival curve assay (Fig. 3.24). However, no reduction in cell count was observed 
following heat induction. 
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Figure 3.22. Phenotypic assay for heat-induction of ecoR expression in M. smegmatis 
mc2155::pYSM13-1. The culture was transferred from 30 °C to 42 °C at 6 hrs. The values 
are from three independent assays. 
 
3.2.4 Isolation of bacteriophages plaquing on M. smegmatis. 
It was unclear why the temperature-sensitive switch in M. smegmatis was functional on 
solid medium but not in broth. One possibility was inefficient expression of ecoR and 
cI857 in the latter condition. To investigate whether insertion of transcriptional promoters 
upstream of either or both of these genes would allow the switch to function in broth, 
bacteriophages plaquing on M. smegmatis were isolated from various soil samples (Table 
3.7), under the assumption that these phages will provide a strong promoter for the 
mycobacterial host. 
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Table 3.7. Isolation of phages plaquing on M. smegmatis 
Soil location No. plaques 
Rosebank, South Africa 0 
Melville, South Africa 0 
Sandton, South Africa ~10 
Wits, South Africa 2 
Parys, South Africa 0 
Yeoville Park, South Africa 0 
Palm Ridge, South Africa 0 
Palm Ridge 2, South Africa 6 
Emmarentia, South Africa 2 
El Vecino, Mozambique 1 
Ciudad de Rodrigo, Mozambique 1 
Maputo, Mozambique 3 
Bilene, Mozambique 10 
Chiba, Japan 5 
Hakone, Japan 4 
Pasadena, USA 2 
Caltech, USA confluent lysis 
Los Robles, USA confluent lysis 
Berlin, Germany 0 
 
3.2.5 Construction of promoter-probe vector for Mycobacterium 
To isolate a promoter from phages, a promoter-probe vector to supplement pNVCAT (Fig. 
3.16) was constructed. For this vector, the green fluorescent protein (gfp) gene contained 
within a 800 bp HindIII-BamHI fragment from pJM608 was ligated into pNV18 (Fig. 
3.25). The resulting vector, pNVGFP, had a unique HindIII site upstream of a promoter-
less gfp gene in a pNV18 backbone. 
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Figure 3.23. Construction of pNVGFP. 
 
 
 
3.3 Analysis of nucleotide bases in Rhodococcus phage nucleic acid 
 
3.3.1 Potential presence of modifications or unusual bases in phage nucleic acid 
In a previous study (Shibayama, 2007), the genomic DNA from Rhodococcus phage 
WTS1 was resistant to restriction by HindIII, BglII, BclI, PstI, siI, BmyI, SfuI, and ClaI. 
Following digestion by XhoII, the DNA could not be cloned into the BglII site of pDA71 
(Quan and Dabbs, 1993). DNA from phage KZA1 was resistant to AccI in addition to all 
of the enzymes above. Cloning of its BamHI-digested DNA into the BglII site of pDA71 
was also unsuccessful. As there was a possibility that these results were due to the 
potential presence of modifications or unusual bases in the phage DNA, it was necessary 
to gain further evidence to support this hypothesis. Methods chosen were HPLC and TLC. 
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3.3.2 Analysis by HPLC 
Nucleosides from each phage were separated by HPLC. Several important controls were 
included. These were DNA from E. coli phages λ (no unusual base) and T4 
(hydroxymethylcytosine) and B. subtilis phages PBS1 (uracil) and SPO1 
(hydroxymethyluracil). The HPLC profiles obtained for all samples are illustrated in 
Figure 3.17. The identities of peaks for the regular bases were according to previous 
studies (Kaneko et al., 1986; Katayama-Fujimura et al., 1984; Tamaoka and Komagata, 
1984), and the retention time of each base was as follows: deoxycytidine, 2.76 minutes; 
deoxyguanidine, 5.03 minutes; deoxythymidine, 6.06 minutes; deoxyadenosine, 10.65 
minutes. For E. coli MM294-4 and phage λ, similar peaks were obtained. The profile for 
phage T4 contained a new peak with a retention time of 1.78 minutes, which probably 
corresponded to hydroxymethyldeoxycytidine, while the deoxycytidine peak had 
disappeared. For phage PBS1, the profile reflected the complete absence of 
deoxythymidine and the presence of different base with a retention time of 3.71 minutes, 
probably corresponding to deoxyuridine. The profile for phage SPO1 also had the 
deoxythymidine peak replaced by one with a retention time of 3.71 minutes, probably 
corresponding to hydroxymethyldeoxyuridine. This assumption was supported by the fact 
that the commercial sample of this unusual base gave a similar peak. It should be noted 
that deoxyuridine and hydroxymethyldeoxyuridine had the same retention time. For R. 
erythropolis and its phages WTS1, KZA1, and PGS1, the profiles were similar to one 
another, and nothing irregular was observed, suggesting absence of unusual bases. For S. 
aureus phage KG3 (Green, 2007), no unusual peak could be observed either. 
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Figure 3.24. HPLC profiles of nucleosides from phages and their hosts. Calf thymus 
DNA, phage λ DNA, and hydroxymethyluracil were commercially obtained. The 
identities of peaks for the regular bases were according to previous studies (Katayama-
Fujimura et al., 1984; Tamaoka and Komagata, 1984; Kaneko et al., 1986). *These peaks 
were speculated to represent the unusual bases, as they were not present in their hosts. dC, 
deoxycytidine; dG, deoxyguanidine; dT, deoxythymidine; dA, deoxyadenosine; dU, 
deoxyuridine; hm dC, hydroxymethyldeoxycytidine; hm dU, hydroxymethyldeoxyuridine. 
 
3.3.3 Analysis by TLC and Mass spectrometry (MS) 
Further analysis was undertaken by TLC (Fig. 3.25). Deoxyribonucleoside 
monophosphates from commercially obtained herring sperm DNA gave four spots. DNA 
from two bacteria included in this analysis, ocardia mexicana and Staphylococcus 
aureus, both gave spots at similar positions as the herring sperm DNA. Analysis by MS 
(undertaken by Dr. Yoshihisa Sei, Kagawa School of Pharmaceutical Sciences, 
Tokushima Bunri University, Kagawa, Japan) revealed the identity of the four spots from 
the S. aureus DNA, as indicated in Figure 3.25. Spots from phage T4 reflected the 
missing cytosine, but one corresponding to hydroxymethyldeoxycytosine monophosphate 
was also missing, probably due to co-migration with one of the three other bases. 
Similarly, for phages PBS1 and SPO1, spots for deoxythymidine monophosphate was 
missing, but those for the unusual bases had probably co-migrated with one of the regular 
ones, thus only three spots were observed. For phage λ, an extra spot was observed 
between those for deoxythymidine monophosphate and deoxyguanidine monophosphate. 
Further purification by HPLC revealed the presence of two molecules from this spot, one 
of which was revealed to be adenosine monophosphate, and the other remains 
unidentified. For Rhodococcus phage FND1, two unusual spots were present. One of 
these was at a similar position as the extra spot from λ, and MS analysis revealed it to be 
adenosine monophosphate (i.e. from RNA). From the other extra spot, occurring between 
deoxyguanidine monophosphate and deoxyadenosine monophosphate, two different 
molecules were detected, one of which was identified again as adenosine monophosphate 
while the other could not be identified. No irregular spots could be observed with phage 
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WTS1. For S. aureus phage KG3, two unusual spots were observed at similar positions as 
phage FND1. However, identity of the top one could not be revealed by MS analysis. 
Two molecules were detected from the bottom spot, whereby one turned out to be 
guanidine monophosphate and the other adenosine monophosphate. 
 
 
Figure 3.25. TLC profiles of nucleotides from bacteria and phages. Profiles were drawn 
(due to lack of appropriate photographic equipment) according to observation of the TLC 
plates under the UV light. Arrow indicates the direction of migration on the TLC plate. 
Identities of spots as determined by MS are shown. dCM, deoxycytidine monophosphate; 
dTM, deoxythymidine monophosphate; dGM, deoxyguanidine monophosphate; dAM, 
deoxyadenosine monophosphate; rGM, guanidine monophosphate; rAM, adenosine 
monophosphate; ND, identity could not be determined. *strain unknown. 
 
3.3.4 Ribosomal contamination of phage preparations 
Out of the five irregular spots observed above, at least four of them contained 
ribonucleoside monophosphates, which raised the suspicion that those phage preparations 
were contaminated with host RNA. Phage preparation generally involved precipitation of 
phage particles from a high-titre lysate using PEG 6000 followed by purification in 
caesium chloride, which could be either a step or an equilibrium gradient. Yamamoto et 
al. (1970) reported the co-precipitation of ribosomes with phage particles by PEG and 
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their subsequent co-purification in a caesium chloride gradient, as ribosomes possess 
similar buoyant density as phage particles. For example, the buoyant density of the 70S 
ribosome is 1.62 g cm-3 (Fenwick, 1971), while that of phages is generally ~1.5 g cm-3 
(Yamamoto et al., 1970). To investigate whether host RNA contamination was the cause 
of the presence of RNA in phage nucleic acid preparations, phage KG3 was re-prepared 
under more stringent conditions. Previously, its lysate was not treated with DNAse and 
RNAse prior to precipitation by PEG, and the purification was done in a step gradient of 
caesium chloride. This time, the lysate was first extensively treated with both RNAse and 
DNAse prior to precipitation using PEG 6000. Following precipitation, the phages were 
purified twice in an equilibrium gradient. When the nucleotides from this newly prepared 
KG3 were separated by TLC, only the four regular spots could be observed (Fig. 3.19), 
suggesting that the two extra spots previously observed had originated from the host 
bacteria, most probably from the ribosomes. This observation was supported by the TLC 
profile of WTS1, which had been purified in an equilibrium gradient and did not produce 
any extra spots either. 
 
 
Figure. 3.26. TLC profiles of nucleotides from phage KG3 purified by step or equilibrium 
(eq.) gradient. 
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4. DISCUSSIO
 
 
4.1 Functional analysis of plasmid pYS1 from ocardia 
 
4.1.1 Detection of plasmids from ocardia 
Plasmids across the whole prokaryotic spectrum are diverse in terms of size, mode of 
replication and transfer, host range, and the set of genes they carry (Thomas, 2000). For 
ocardia, information of this nature is limited, which was a principal reason for my 
characterizing pYS1 from . aobensis. I detected plasmids in pathogenic strains of 
ocardia at a similar frequency to previous reports for this genus (Kasweck et al., 1981; 
Provost et al., 1996; Qasem et al., 1999). Those studies could not attribute any 
phenotypic traits to plasmids harboured, at least not with respect to the properties tested, 
viz. virulence or antibiotic resistance. Although these phenotypes were not dealt with in 
this study, the data support the notion that harbouring of plasmids is not a common 
feature among pathogenic ocardia. It remains unknown whether pYS1 or any other 
plasmid from ocardia contains genes advantageous to its virulence. 
 
4.1.2 Rolling-circle-replication of pYS1 
From both sequence analyses and experimental data, it is clear that pYS1 is a rolling-
circle-type plasmid belonging to the pIJ101/pJV1 (Kendall and Cohen, 1988, Servin-
Gonzalez et al., 1995) family. Motifs usually associated with replication initiation 
proteins of rolling-circle-type plasmids were all identified in the Orf2 amino acid 
sequence.  
In the current model of rolling-circle-replication (Fig. 4.1) (Khan, 2005), leading strand 
synthesis is initiated when the Rep protein makes a nick at the GG dinucleotide at the 
DSO, which was conserved in pYS1 as shown by the multiple alignment of its nucleotide 
sequence to DSO sequences from related plasmids. As expected, the DSO in pYS1 was 
demonstrated to be indispensable for replication when pYS1R1D1, a plasmid containing 
the mutated form of the DSO, was unable to replicate in ocardia.  
As replication proceeds, synthesis of the leading strand causes the old leading strand to be 
displaced and to form a single-stranded intermediate (Khan, 2005), which I detected for 
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pYS1 by Southern hybridization as a band migrating faster than the double-stranded form 
and disappearing upon treatment with S1 nuclease. On the single-stranded intermediate, 
lagging strand synthesis begins because the SSO serves as a signal for RNA primer 
production (Khan, 2005). The SSO is characterized by inverted repeats forming an 
extensive secondary structure (Khan, 2005), which was predicted on pYS1. On one of the 
exposed loop regions, a sequence similar to a conserved CS-6 sequence TAGCGA 
(Kramer et al., 1998a; Khan, 2004) was detected, strengthening the accuracy of my 
prediction. Although overall SSO sequences are not well-conserved among plasmids of 
the same family, predicted secondary structures for two related plasmids, pRE8424 
(Nakashima and Tamura, 2004) of R. erythropolis and pXT107 (Xia et al., 2006) of 
ocardia sp. 107, are depicted for comparison (Fig. 4.2). 
 
 
Figure 4.1. Current model of plasmid rolling-circle replication. Newly synthesized 
strands are indicated in blue. Modified from Khan, 2005. 
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Figure 4.2. Predicted SSO structures of (A) pRE8424 (Nakashima and Tamura, 2004) and 
(B) pXT107 (Xia et al., 2006). Sequences similar to conserved CS-6 sequences are 
indicated by dots. 
 
Four types of SSO have so far been described based on their CS-6 sequences (Table 4.1). 
Of these, the pYS1 SSO is most similar to type A, exemplified by pE194 of S. aureus 
(Kramer et al., 1998a). However, this type of SSO is known to function efficiently only 
in their native host (Khan, 2004), which is contradictory to the broad host-range of pYS1. 
It is therefore clear that these four types of SSO do not make up an exhaustive list and 
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that additional work is necessary to further characterize the pYS1 SSO. Analysis on new 
plasmids should further reveal a greater variety of this element.  
 
Table 4.1. SSO types and their CS-6 sequences 
SSO type CS-6 sequence Plasmid example Host Reference 
A TAGCGT pLS1 
Streptococcus 
pneumoniae 
del Solar et al., 1993 
A TAGCGA pE194 
Staphylococcus 
aureus 
Kramer et al., 1998a 
W TAGCGT pWV01 Lactococcus lactis Seegers et al., 1995 
T CAGCGC pBAA1 Bacillus sp. Devine et al., 1989 
U 
AAGGGT 
& 
GATCTT 
pUB110 
Staphylococcus 
aureus 
Boe et al., 1989 
 
 
In most rolling-circle-type plasmids, mutating or deleting the SSO leads to an 
accumulation of the single-stranded intermediate (Khan, 2005). This is because plasmid 
replication can begin as long as the DSO serves as a signal for replication initiation 
(leading strand synthesis). However, the single-stranded intermediate produced would 
have difficulty initiating lagging strand replication in the absence of a correct SSO 
sequence. As a result, this intermediate form would remain single-stranded, without any 
increase in the number of double-stranded plasmid. The cell would therefore repeatedly 
initiate plasmid replication at the DSO, eventually leading to an exponential increase in 
the number of the single-stranded intermediate (Khan, 2005).  
In pYS1 mutation of the conserved sequence in the SSO, however, did not lead to 
accumulation of single-stranded intermediates (Fig. 3.6). Although this was not the case 
in a previous study concerning pRE8424 (Nakashima and Tamura, 2004), whose 
mutation in a similar region did lead to accumulation of the single-stranded form, it is 
understandable that tampering with a sequence involved in termination of RNA primer 
synthesis (i.e. CS-6) (Kramer et al., 1997; Kramer et al., 1998b) might not necessarily 
cause much instability to plasmid replication.  
On the other hand, the SSO deletion experiment showed the indispensability of the SSO 
region in pYS1 replication. Maximum change tolerable to the secondary structure was 
deletion of the lower stem consisting of 7 bp, leading to a shorter hairpin structure (Fig. 
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3.5, pYS1R3 clone). Further deletions abolished plasmid maintenance, indicating that 
pYS1 does not carry secondary signals for single-strand to double-strand conversion as 
do many rolling-circle plasmids. There is room for future studies on the interaction 
between the RNA primase and different parts of the secondary structure of the SSO. It 
would also be interesting to mutate the first terminal loop of the predicted SSO structure 
while maintaining the same secondary structure. This experiment, however, is not easy as 
the loop is flanked by a perfect inverted repeat whereby primers designed to bind to this 
region would readily undergo both intramolecular and intermolecular annealing.  
 
4.1.3 ocardia- E. coli shuttle vector pYS1R1 
As the SSO deletion experiment revealed the minimal replicon of pYS1 to be within a 2 
kb region containing the rep (orf2), DSO, and SSO, pYS1R1 (Fig. 3.5) can serve as a 
ocardia-E. coli shuttle vector, which, with further manipulation, can result in a more 
useful vector. Potential further manipulations include increasing the number of unique 
cloning sites. Currently, restriction sites for BamHI, EcoRI, SalI, and HincII, which are in 
the multiple cloning site, also exist within rep, limiting their use as cloning sites. Silent 
mutations may be introduced to these sites to eliminate them while keeping the Rep 
amino acid sequence intact.  
To my knowledge, pNV18/19 (Chiba et al., 2007), which uses the replicon from a 
mycobacterial plasmid pAL5000 (Stolt and Stoker, 1996), has been the most useful 
ocardia-E. coli shuttle vector available. Compatibility of the pYS1 and pAL5000 
replicons may serve as an advantage where introduction of two separate plasmids is 
required, not only into ocardia but also into related bacteria such as Mycobacterium 
whose significant number of vectors rely on the pAL5000 replicon (Pashley and Stoker, 
2000). As a broad-host-range replicon, vectors based on pYS1 may also benefit studies 
on Rhodococcus and Gordonia. 
 
4.1.4 pYS1 copy number 
Under the assumption that the . aobensis genome size was not very different from that 
of . farcinica, pYS1 copy number was estimated to be approximately ten per cell. It was 
expected that pYS1 copy number would be similar to that of pAL5000, as the gel 
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indicating coexistence of pYS1 and pNV19, which uses the pAL5000 replicon, showed a 
comparable intensity of fluorescence, implying similar copy number. As the copy number 
of pAL5000 in M. smegmatis is reported to be about five (Ranes et al., 1990), it can be 
concluded that the method of comparing fluorescence intensities between chromosomal 
and plasmid DNA on an agarose gel is suitable for deriving a rough estimate of copy 
number.  
 
4.1.5 orf1 and orf3 of pYS1 
In the well-described Streptomyces plasmid pIJ101 (Kendall and Cohen, 1987), plasmid 
transfer is mediated by the product of the tra gene, whose expression is controlled by a 
Gnt-R type transcriptional repressor KorA. Without this negative regulation, the gene is 
lethal to the host. A similar situation applies to another Streptomyces plasmid pSN22 
(Kataoka et al., 1991), where expression of traB is controlled by the traR product. As 
TraB was shown to be localized to the cell membrane (Kosono et al., 1996), it has been 
speculated that its uncontrolled production leads to interference with membrane integrity. 
In both pIJ101 and pSN22, the gene encoding this transcriptional repressor occurs just 
upstream of the transfer gene, separated by a short intergenic region, and is transcribed in 
the opposite direction (Kendall et al., 1987; Kataoka et al., 1991) (Fig. 4.3). Expression 
of both genes is regulated by a bidirectional promoter occurring in this intergenic region 
(Kendall et al., 1987; Kataoka et al., 1991).  
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Figure 4.3. Schematic map of pIJ101 showing the positions of tra and korA (Stein et al., 
1989). p-korA and p-tra refer to the bidirectional promoter in the intergenic region. 
 
In pYS1, Orf1 presented a curious case, as its lethality was consistent with its sequence 
resemblance to Tra, but its lack of obvious involvement in plasmid transfer, as judged by 
the transfer frequencies of the insertion mutants, was inconsistent with it. It should be 
noted, however, that there is a possibility that each of the five locations disrupted upon 
construction of the insertion mutants, was involved in conjugation, in which case the 
transfer frequency would have been reduced in all mutants. This situation would be true if 
both orf3-orf1 intergenic region (disrupted for pYS1K2) and orf2-orf3 intergenic region 
(disrupted for pYS1K5) play a role in plasmid transfer as much as orf1. Otherwise, 
similar conjugation frequencies arising from mutants disrupted within orf1 or outside it 
indicate its lack of involvement in plasmid transfer and the presence of other signals 
which mediate this function.  
Data from transformations suggested that orf1 may instead be involved in plasmid 
stability, as it took significantly longer for colonies to arise when various species were 
transformed with an orf1-disrupted plasmid, as compared to those transformed with a 
plasmid disrupted in the orf3-orf1 intergenic region. This retardation was observed for 
just one of the four ocardia species but for all of the six Mycobacterium, Gordonia, and 
Rhodococcus species (Table 3.5). The effect was not simply due to slower growth of 
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these transformants, and while it may be premature to draw conclusions from these 
observations, it is tempting to speculate that orf1 is involved in plasmid stability when 
establishing itself in a new host, probably through a cell-membrane-associated 
mechanism. 
The phenotyptic CAT-assay suggested the presence of a promoter for orf1 in the orf3-
orf1 intergenic region of at least ~650 bp, but no promoter activity could be detected for 
orf3 in the same region. There may be an orf3 promoter in this region which escaped 
detection, or it may be further upstream in a region overlapping orf1. Orf3, despite its 
lack of sequence similarity to anything in the database, was shown to be a novel 
transcriptional repressor and is analogous to KorA of pIJ101 or TraR of pSN22 in that it 
acts as a “kil-override” (Stein et al., 1989). This is an interesting situation, as the orf1-
orf3 pair in pYS1 is similar to the tra-korA pair in pIJ101 in terms of gene organization 
and both pairs having a related lethal gene, and yet the transcriptional repressor from each 
pair is distinctly different from one another. Further studies are necessary to better 
understand the repressor encoded by orf3 and to narrow down the region to which where 
it binds. The orf3-orf1 intergenic region must also be involved in plasmid stability, as 
pYS1K2, an insertion mutant disrupted within this region, was readily lost from the host 
cell during curing, while original pYS1 seemed stable after 90 generations.  
 
4.1.6 Concluding remarks on pYS1 
In summary, I have shown pYS1 is a cryptic, broad-host-range, rolling-circle-type 
plasmid from . aobensis. While similarities with other Gram-positive plasmids exist, 
pYS1 has major differences from some well-described plasmids in that it has a more 
stringent control for lagging strand synthesis and the lethal function of a gene which 
seems to be involved in stability is controlled by a newly described transcriptional 
repressor. This study highlights the diversity of plasmids, not only with respect to pYS1 
and those previously described, but also the nearly-infinite variety which may exist across 
the whole prokaryotic spectrum. 
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4.2 Construction of an inducible expression system for the analysis of antimicrobial 
genes from Rhodococcus phages 
Tuberculosis causes two million human deaths annually, and its causative agent, M. 
tuberculosis, is one of the most successful bacterial pathogens (Okada and Kobayashi, 
2007). The emergence and prevalence of multi-drug resistant strains (Cox et al., 2010) 
call for identification of novel drug targets. At least five out of nine previously isolated 
Rhodococcus phage genes were inhibitory to M. smegmatis, providing hope that products 
encoded by these genes may lead to identification of such targets. To study these genes, it 
is necessary to have a system where their expression can be induced, which will allow 
comparison of the host cell before and after induction. Therefore an attempt was made to 
develop an inducible expression system in M. smegmatis. 
For the construction and testing of such a system, a gene encoding a known inhibitory 
product which would serve as a model was required. For this purpose ecoR, encoding a 
restriction endonuclease, was selected. Because pEcoR251 contained this gene under the 
control of the λ PR promoter, the plasmid was selected as the backbone of the inducible 
system. In a λ lysogen, the cI repressor binds to this promoter and prevents expression of 
cro in order to maintain the lysogenic state (Ptashne, 2004). As expression of cro will 
cause the phage to enter the lytic cycle, the cI repressor should not allow any leaky 
expression to occur. For this reason, a switch consisting of PR and cI seemed ideal for 
inducing expression of toxic genes. A temperature-sensitive mutant cI857 was chosen, as 
this would allow the repressor to lose functionality upon transfer from 30 °C to 42 °C. 
Although the heat-inducible switch using pYS13 and pYS13-1 in E. coli worked 
effectively, pYSM13-1 did not allow induced killing of M. smegmatis cells in broth. As 
the switch was functional on solid media, differences in growth conditions between solid 
and liquid media and their effect on cell physiology need to be considered to identify the 
potential cause. As one such cause may be the lack of expression of ecoR and cI857 in 
broth, phages plaquing on M. smegmatis were isolated as a source of strong 
mycobacterial promoters. Future work includes using either pNVCAT or pNVGFP to 
isolate a phage promoter and test its effect on the inducible system. 
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4.2.1 Concluding remarks on phage genes inhibiting mycobacteria 
The existing diversity of phages and their genes (Breitbart et al., 2002; Hatfull et al., 
2010; Kwan et al., 2005; Kwan et al., 2006) present a potentially enormous pool from 
which a large number of novel bactericidal mechanisms may be identified. The 
Rhodococcus phage genes which proved inhibitory to M. smegmatis may provide us with 
new susceptibility targets. Further work is necessary to construct the cI857-PR system in 
M. smegmatis. An inducible expression system with a tight genetic switch functional in 
this organism will allow further characterization of the products encoded by the phage 
genes. 
 
 
4.3 Analysis of nucleotide bases in Rhodococcus phage nucleic acid 
While the deoxyribonucleic acids of Rhodococcus phages WTS1 and KZN1 were 
resistant to restriction by many enzymes and attempts to clone their DNA in E. coli were 
unsuccessful in a previous study (Shibayama, 2007), more direct evidence was required 
to suggest an involvement of modifications or unusual bases. HPLC and TLC were 
chosen for this purpose, as they could separate individual bases according to their 
chemical properties and sizes. Molecules behaving differently to the regular bases were 
then analysed by mass spectrometry to elucidate their chemical structures. 
For HPLC, the differences in peak times between a sample containing only the canonical 
bases (e.g. E. coli MM294-4) and those containing hydroxymethylcytosine (T4), uracil 
(PBS1), or hydroxymethyluracil (SPO1) suggested the credibility of this method in the 
detection of such bases. However, the times at which peaks for the two latter unusual 
bases appeared were identical, suggesting that different bases could not always be 
separated under the conditions used. For the Rhodococcus phages, nothing unusual could 
be detected in their HPLC profiles, which, therefore, was in contradiction with the 
previous study.  
For TLC, spots for the unusual bases from T4, PBS1, and SPO1 were missing, suggesting 
that they had probably co-migrated with one of the regular bases. The absence of one of 
the regular bases from each of these phages, however, was clearly reflected by a missing 
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spot. Therefore, under the conditions used, TLC may only be useful when running a 
sample in which one of the regular bases is completely or mostly absent.  
The detection of ribonucleotides from phages FND1, KG3, and λ indicated the stringency 
required when purifying phages for subsequent analysis of their nucleic acids. As these 
three phages were purified in a step gradient of caesium chloride, host RNA 
contamination was the most likely explanation, as Yamamoto et al. (1970) reported the 
co-precipitation of ribosomes by PEG and their subsequent co-purification with phage 
particles in caesium chloride. Phage WTS1, which was purified in an equilibrium 
gradient, did not show any extra spots, suggesting that finer gradients prevent this 
contamination. The choice of gradient was confirmed to be a crucial factor when nucleic 
acid from KG3, re-purified in an equilibrium gradient, did not show the extra spots seen 
earlier. 
 
4.3.1 Concluding remarks on phage unusual/modified bases 
As shown for T4, PBS1, and SPO1, irregularities in their DNA were reflected by both 
HPLC and TLC. Therefore a combination of these methods was an effective way to 
detect unusual bases, although TLC required as much as 20 µg of DNA per run and 
therefore not efficient. No unusual bases could be detected in the Rhodococcus and 
Staphylococcus phages by these methods. The resistance of DNA from WTS1 and KZN1 
to restriction digestion and difficulty in cloning them in my previous study remain to be 
explained: it may be due to a dearth of palindromic sequences recognized by the 
restriction endonucleases used and/or it is of technical origin. 
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5. APPE
DIX 
 
5.1. Media 
 
LB  3 g tryptone 
  1.5 g sodium chloride 
  1.5 g yeast extract 
  300 ml distilled water 
 
LB agar 3 g tryptone 
  1.5 g sodium chloride 
  1.5 g yeast extract 
  4.5 g agar 
  300 ml distilled water 
 
Sloppy agar 1 g tryptone 
  0.5 g sodium chloride 
  0.5 g yeast extract 
  0.75 g agar 
  100 ml distilled water 
 
BHI  11.1 g brain heart infusion 
  300 ml distilled water 
 
BHI agar 11.1 g brain heart infusion 
  4.5 g agar 
300 ml distilled water 
   
Rhodococcus regeneration medium 
  3 g tryptone 
  1.5 g yeast extract 
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  0.9 g sodium chloride 
  30.9 g sucrose 
  1 g glucose 
  1 g magnesium chloride hexahydrate 
  250 ml distilled water 
Solution was microwaved to dissolve sucrose. Then, 5.5 g agar was added, autoclaved, 
and cooled to 60°C, after which the following were added: 
  10 ml 0.25 M TES pH 7.2 
  6 ml 1 M calcium chloride 
  3 ml 0.5% potassium dihydrogen orthophosphate 
  1.5 ml 10 mg/ml nystatin 
  0.9 ml 10 mg/ml rifampicin 
Plates of constant volume of 25 ml were poured on a horizontal surface. 
 
 
5.2. SOLUTIO
S FOR PHAGE PURIFICATIO
 
 
SC buffer 0.58 g sodium chloride 
  0.2 g calcium chloride hexahydrate 
  5 ml 1 M tris-hydrochloride pH 8.0 
  0.5 ml 2% gelatin 
  95 ml distilled water 
 
2% Gelatin 0.02 g gelatin 
  1 ml distilled water 
 
Caesium chloride solutions for gradient centrifugation 
(Density values are relative to that of water at 20 °C) 
 
 1.45 g/ml 3.53 g caesium chloride 
   5 ml SC buffer 
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 1.50 g/ml 4.09 g caesium chloride 
   5 ml SC buffer 
 
 1.70 g/ml 6.33 g caesium chloride 
   5 ml SC buffer 
 
5.3. SOLUTIO
S FOR D
A PREPARATIO
 
 
Solution I 0.9 g glucose 
  2.5 ml 1 M tris-hydrochloride pH 8.0 
  2 ml 0.5 M EDTA  
  95.5 ml distilled water 
 
Solution II 0.8 g sodium hydroxide 
  1 g SDS 
  100 ml distilled water 
 
Solution III 60 ml 5 M potassium acetate 
  11.5 ml glacial acetic acid 
  28.5 ml distilled water 
 
1 M tris-hydrochloride pH 8.0  
12.1 g tris base, dissolved in distilled water 
  pH adjusted to 8.0 with hydrochloric acid 
  Distilled water added to 100 ml 
 
0.5 M EDTA pH 8.0   
18.61 g EDTA, dissolved in distilled water 
  pH adjusted to 8.0 with sodium hydroxide 
  Distilled water added to 100 ml 
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TE  1 ml 1M tris-hydrochloride pH 8.0 
  2 ml 0.5 M EDTA pH 8.0 
  100 ml distilled water 
 
10% SDS in water 
  1 g SDS 
  10 ml distilled water 
 
10% SDS in TE 
  1 g SDS 
  10 ml TE buffer 
 
4.5 M potassium acetate pH 6.0 
  3.7 g sodium acetate 
  pH adjusted to 6.0 with acetic acid 
  Distilled water added to 10 ml 
 
TE-saturated phenol 
  10 g phenol 
  10 ml TE 
 
1 M sodium chloride 
  5.8 g sodium chloride 
  100 ml distilled water 
 
1% Ribonuclease 
  0.01 g ribonuclease 
  1 ml distilled water 
   Boiled for 10 min before use 
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Dialysis buffer 
  0.58 g sodium chloride 
  2.2 g calcium chloride hexahydrate 
  50 ml 1 M tris-hydrochloride pH 8.0 
  950 ml distilled water 
 
5.4. SOLUTIO
S FOR ELECTROPHORESIS 
 
5× TBE 54 g tris base 
  27.5 g boric acid 
  20 ml 0.5 M EDTA pH 8.0 
  Distilled water added to 1000 ml 
 
Agarose gel 0.8 g (for 0.4%), 1.6 g (for 0.8%), or 2.8 g (for 1.4%) agarose 
  20 ml 5× TBE 
  180 ml distilled water 
 
Running buffer 
  20 ml 5× TBE 
  180 ml distilled water 
  20 µl 1% EtBr  
 
1% EtBr 0.1 g EtBr 
  10 ml distilled water 
 
Tracking dye 0.01 g bromophenol blue 
  0.01 g xylene cyanol 
  10 ml 30% glycerol in TE 
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5.5. SOLUTIO
S FOR TRA
SFORMATIO
 
 
Calcium chloride transformation buffer 
  4.38 g calcium chloride hexahydrate 
  2 ml 1 M tris-hydrochloride 
  198 ml distilled water 
 
Electroporation buffer 
  20.5 g sucrose 
30 ml glycerol 
  170 ml distilled water 
 
Basal (B) buffer 
  10.3 g sucrose 
  0.025 g potassium sulfate 
  0.202 g magnesium chloride hexahydrate 
  10 ml 0.25 M TES pH 7.2 
 
Protoplast (P) buffer 
  2 ml B buffer 
  20 µl 0.5% potassium dihydrogen orthophosphate 
  50 µl 1 M calcium chloride 
 
P-PEG buffer 
  0.5 g PEG 6000 
  1 ml P buffer 
  PEG sterilized by UV irradiation for 10 min and vortexed vigorously  
  to dissolve. 
 
20% glucose 4 g glucose 
  20 ml distilled water 
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0.25 M TES 
  17.2 g TES, dissolved in distilled water 
  pH adjusted to 7.2 with sodium hydroxide 
  Distilled water added to 300 ml 
 
1 M calcium chloride 
  21.9 g calcium chloride hexahydrate 
  100 ml distilled water 
 
0.5% potassium dihydrogen orthophosphate 
  0.5 g potassium dihydrogen orthophosphate 
  100 ml distilled water 
 
5.6. Solutions for Southern blot and hybridization 
 
0.25 M hydrochloric acid  
1.6 ml hydrochloric acid 
  198.4 ml distilled water 
 
0.5 
 sodium hydroxide  
4 g sodium hydroxide 
  200 ml distilled water 
 
20× SSC 175.3 g sodium chloride 
  88.2 g sodium citrate 
  pH adjusted to 7.0 with hydrochloric acid   
Distilled water added to 1000 ml 
Solution was diluted accordingly with distilled water to give 10×, 5×, 2×, and 0.1×. 
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Hybridization solution 
  0.02 g N-lauroylsarcosine 
  0.004 g SDS 
  0.2 g blocking reagent (Roche) 
  20 ml 5× SSC 
  Dissolved at 60 °C for 1 hr. 
 
0.1% SDS in 2× SSC 
  0.1 g SDS 
  100 ml 2× SSC 
 
0.1% SDS in 0.1× SSC 
  0.1 g SDS 
  100 ml 0.1× SSC 
 
5.7. Solutions for chromatography 
 
3 M ammonium sulphate 
198.2 g ammonium sulphate 
500 ml distilled water 
 
1 M sodium acetate 
8.2 g sodium acetate 
100 ml distilled water 
 
20 mM ammonium dihydrogen phosphate 
2.3 g ammonium dihydrogen phosphate 
1000 ml distilled water 
  
5.8. A
TIMICROBIAL AGE
TS 
Antimicrobial agents are listed in Table 5.1. 
 117 
Table 5.1 Antimicrobial agents 
Agent 
Stock concentration 
(mg/ml) 
Solvent 
Ampicillin 100 70% ethanol, 30% distilled water 
Chloramphenicol 4 or 20 ethanol 
Kanamycin 100 distilled water 
Nalidixic acid 10 70% ethanol, 30% distilled water 
Nystatin 10 methanol 
Rifampicin 10 methanol 
Streptomycin 20 distilled water 
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